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Abstract  
 Natural products are bioactive secondary metabolites produced by living 
organisms and are prevalently utilized as pharmaceutical drugs.  Marine adapted 
organisms are a promising source of new natural products possessing unique 
chemical structures and biological activities. By studying the biosynthetic 
pathways employed by living organisms to produce natural products, insights into 
new strategies to generate molecules to combat disease and overcome drug 
resistance may be gained. This thesis study aimed to uncover the biosynthetic 
pathway employed by a marine actinomycete, Nocardiopsis sp. CMB-M0232, to 
catalyze the assembly of the nocardioazines. These molecules are a group of 
2,5-diketopiperazine natural products that feature structurally unique functional 
groups. Nocardioazine A, the hypothesized end product of the nocardioazine 
biosynthetic pathway, exhibits anticancer activity. Bioinformatics analyses 
revealed three biosynthetic gene clusters from Nocardiopsis encoding proteins 
with hypothesized roles in nocardioazine A biosynthesis. Two cyclodipeptide 
synthases (CDPSs), NozA and NcdA, were biochemically characterized in vivo 
and in vitro to reveal that both are substrate specific enzymes that utilize 
tryptophan-charged tRNA substrates to catalyze assembly of cyclo(L-Trp-L-Trp), 
a proposed precursor of nocardioazines. Fidelity is uncommon amongst 
characterized CDPSs, making NozA and NcdA important CDPS family additions. 
This study also aimed to characterize NozD and NozE, two cytochrome P450 
homologs with predicted roles as diketopiperazine-tailoring enzymes. 
Heterologous expression of these enzymes in Streptomyces strains was not able 
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to confirm the functions of NozD and NozE but set the stage for future studies to 
optimize conditions for probing their roles in nocardioazine A biosynthesis. The 
results gathered from this study, along with future work to better understand the 
engineering of unique functional groups from Nocardiopsis may provide 
opportunities to produce new bioactive molecules.  
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Chapter I 
Introduction 
 
Marine microorganisms: goldmines of natural products 
Modern medicine requires an ongoing search for new, clinically useful 
drugs to combat disease and overcome drug resistance. It is estimated that less 
than one third of over 30,000 human diseases have treatment options and those 
options continue to diminish as antibiotic resistance increases at a faster rate 
than the development of new antibiotics (Subramani et al. 2012, Netzker et al. 
2015). A promising source of new drugs is natural products, bioactive secondary 
metabolites produced by living organisms. These molecules can be utilized as 
medicines such as antibacterials, anticancer agents and anti-inflammatory drugs 
(Newman and Cragg, 2012).    
Primary metabolites are molecules directly involved in the growth, 
development, and reproduction of an organism; these include fats, proteins, 
carbohydrates and nucleic acids. Natural products are secondary metabolites, 
which are not necessary for growth, development or reproduction, but are 
commonly used as agents to increase their competitive fitness. For example, 
some natural products are utilized as chemical defenses for organisms to adapt 
to their environment and survive amongst predators or pathogens (Dias et al. 
2012). Organisms, including plants, fungi, algae and bacteria, produce natural 
products by way of biosynthesis, enzyme-catalyzed processes where simple 
chemical building block substrates are converted into more complex products 
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(Dias et al. 2012). Secondary metabolites are generally assembled by 
specialized metabolic pathways that utilize intermediates from primary metabolic 
processes such as photosynthesis and glycolysis. These biosynthetic pathways 
presumably evolved due to selective pressure from biotic and abiotic factors such 
as viruses, environmental shifts and radiation, producing new metabolites that 
allow organisms to adapt and prolong their existence. Because living organisms 
adapt to and overcome a diverse variety of environments and predators, the 
secondary metabolites produced tend to be unique to the organism (Dias et al. 
2012).  
Historically, natural products have been the leading source of new drugs, 
offering novel and complex chemical structures that are often too difficult to 
produce via traditional synthetic chemistry. The 21st century has presented great 
strides in the field of natural product drug discovery due to advances in molecular 
biology, bioinformatics and sequencing technologies. These advances provide 
fast access to genomic information, identification of biosynthetic pathways and 
the necessary tools to utilize this information and facilitate drug discovery (Lane 
and Moore, 2011). Interdisciplinary collaborations such as those between 
biologists, chemists and engineers are also credited with the expansion of this 
field. Networking among experts has resulted in a better understanding of the 
biosynthesis of structurally novel, bioactive natural products as well as how that 
structure links them to their physiological and ecological roles (Dalisay et al. 
2013). Use of these modern approaches has greatly facilitated scientists’ efforts 
to study biosynthetic pathways and their products (Giessen and Marahiel, 2012). 
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For example, recombinant protein expression, used in the current thesis study, 
exploits expression hosts such as E. coli or yeast to study the products of 
enzymatic synthesis. This biomolecular approach to synthesis provides an 
environmentally friendly alternative to synthetic chemistry by using far less toxic 
chemicals, therefore offering a less harmful experimental strategy for scientists 
and for the environment (Dias et al. 2012). 
Of the many organisms that yield natural products, microorganisms are 
the leading producers. An unrivaled number (>70%) of novel compounds have 
been derived from actinomycetes, bacteria that are members of the order 
Actinomycetales such as the genera Actinomadura, Nocardiopsis, Salinispora 
and Stremptomyces (Manivasagan et al. 2014).  Most of these compounds were 
derived from terrestrial actinomycetes, which were found to be prolific producers 
of structurally and chemically diverse metabolites. However, following over four 
decades of exploration, terrestrial organisms have been largely exhausted as 
sources of new drugs due to repetitive discovery of identical compounds. 
Research has now shifted significantly toward marine actinomycetes, which are 
found in abundance throughout the ocean, from plant- and sponge-associates to 
ocean floor sediments (Dalisay et al. 2013, Manivasagan et al. 2013). Marine 
adapted organisms hold great potential as sources of new bioactive compounds 
possessing unique chemical structures and biological activities. It is hypothesized 
that differences in environmental conditions of marine and terrestrial species may 
result in different secondary metabolites in marine organisms compared to those 
found in terrestrial organisms. Seventy percent of the Earth’s surface is covered 
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in water that may contain approximately one million cells per milliliter, setting the 
stage for nearly infinite sources of new, marine microorganisms and natural 
products (Subramani et al. 2012, Williams 2009).   
Lane and Moore (2011) discussed the concept of the marine natural 
product “Dogma” to describe the connection between genes, enzymes and 
natural products when studying natural product biosynthetic pathways.  Studying 
how organisms employ genes and enzymes to produce natural products offers 
insight into new ways to combat disease and overcome drug resistance by 
providing opportunities to modify existing natural products and discover new 
bioactive metabolites (Jensen and Fenical, 2006). 
 
Natural product biosynthetic pathways: the keys to unlocking the potential 
of organisms to produce natural products 
 There are several obstacles faced in marine natural product drug 
discovery that have been overcome by advancements in molecular genetics and 
analytical tools. For example, despite the known presence of novel bioactive 
compounds in marine actinomycetes, their use as drugs is hindered due to the 
minimal quantities often produced by the organisms. Modern mass spectrometry 
(MS) enables the detection of these miniscule quantities of secondary 
metabolites, and offers understanding of molecular formulas and structural 
insights.  Even with the knowledge of their presence, the isolation of compounds 
in reasonable quantities for drug development from the native organisms is highly 
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challenging. A historical remedy to this issue has been chemical synthesis, but 
synthetic approaches face roadblocks in the case of many natural products due 
to their complex chemical structures. A study presented by Long et al. (2005) 
represents one of the first examples of gene-based strategies to biosynthesize 
cyclic dipeptides, the patellamides, from the cyanobacterium, Prochloron 
didemni. The researchers cloned the entire patellamide biosynthetic gene cluster 
from P. didemni into a heterologous host, E. coli, biosynthesizing the 
petallamides in larger quantities than available from the native producing 
organism. They also discovered that upon mutating single genes in the 
biosynthetic pathway, several variations of the cyclic-peptide natural products 
were synthesized, exploiting what is referred to as combinatorial biosynthesis.  
An alternative to in vivo biosynthesis is in vitro biosynthesis, an approach 
that exploits enzymes as biocatalysts to generate complex metabolites outside of 
a heterologous host. By combining such enzymes with desired precursors in 
vitro, studies have been able to achieve total synthesis of many structurally 
complex compounds. In addition, in vitro biosynthesis presents the opportunity to 
exploit enzymes to decorate existing natural products with new functional groups, 
and therefore alter their bioactivity. These types of molecular biology approaches 
have allowed us to elucidate the origins of many secondary metabolites, exploit 
biosynthetic machinery to produce greater quantities of secondary metabolites 
and produce new, bioactive derivatives of known compounds (Gulder and Moore, 
2010, Lane and Moore, 2012, Smanski et al. 2012).  
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Another obstacle that recent studies have begun to investigate is the 
notable difference between the large presence of bioinformatics-predicted 
biosynthetic gene clusters from microbial genomes compared to the dramatically 
smaller number of secondary metabolites observed under standard laboratory 
conditions (Netzker et al. 2015). For example, genome sequencing of the marine 
actinomycete Salinispora tropica revealed that almost 10% of its 5-Mbp genome 
was predicted to have involvement in the biosynthesis of at least 19 different 
types of secondary metabolites. Contrary to this number of compounds capable 
of being produced, standard laboratory conditions only yielded four different 
classes of secondary metabolites from S. tropica (Gulder and Moore, 2009; Lane 
and Moore, 2011). Application of molecular biology techniques, such as gene 
elimination mutations, has led to discovery of additional metabolites encoded by 
the genome (Lane and Moore, 2011). This observation has been noted among 
genomes of many bacteria and fungi, suggesting a wealth of new bioactive 
metabolites that are not accessible by standard fermentation conditions in the 
laboratory (Challis, 2007, Giessen and Marahiel, 2012).  
Several hypotheses exist for the evolutionary maintenance of such energy 
consuming secondary metabolic pathways, with roles described in habitat 
defense, predator inhibition and as intraspecific signaling molecules. The majority 
of secondary metabolic pathways appear to be conditionally expressed, only 
turned on under specific environmental conditions (Netzker et al. 2015). This 
fine-tuned pathway expression may offer many benefits to the organism. For 
example, if secondary metabolite pathways were continually expressed in their 
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native environment, neighbors exposed would quickly develop resistance and 
therefore defeat the purpose of the metabolites, which are commonly used for 
defense.  
General fermentation conditions used in laboratories do not typically 
trigger production of such compounds. By employing methods such as 
combinatorial biosynthesis and heterologous expression, researchers are 
beginning to unlock the mechanisms to express these silent gene clusters in 
organisms and reveal their potential as significant natural product producers 
(Ozaki et al. 2013). Through the coevolution of species and their secondary 
metabolites over time, nature may lead us to new, naturally evolved and modified 
pathways providing us new metabolites and the means to synthesize altered 
metabolites (Dias et al. 2012).   
 
Nocardioazines: structurally unique natural products from a marine 
actinomycete 
Nocardiopsis sp. CMB-M0232 is a marine actinomycete that was first 
isolated from sediment samples collected off the coast of Australia in 2009 by Dr. 
Robert J. Capon and co-workers. Capon and his research team discovered that 
Nocardiopsis sp. CMB-M0232 produced a plethora of interesting, biomedically 
active secondary metabolites (Raju et al. 2010, Raju et al. 2011, Raju et al. 
2013). For example, nocardiopsins A-D were isolated from this strain, and are 
the only members of the macrolide-pipecolate natural product family discovered 
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in over ten years (Raju et al. 2011, Raju et al. 2013). The biosynthetic pathway 
responsible for the production of nocardiopsins A-D from Nocardiopsis sp. was 
recently elucidated by the Lane group (Bis et al. 2015).  
Another novel class of compounds isolated from Nocardiopsis sp. are the 
nocardioazines (Figure 1), novel prenylated 2,5-diketopiperazines (DKPs)  
(Figure 2) (Raju et al. 2011). DKPs are secondary metabolites known for their 
potential medical application as antibacterials, antitumor agents and 
immunosuppressives. Special attention has been placed on 2,5-DKP natural 
products due to the large number isolated from microorganisms. DKPs are the 
simplest cyclic peptides, formed when two amino acids undergo condensation, 
resulting in the formation of two peptide bonds that produce a cyclodipeptide 
(CDP) (Figure 2) (Borthwick 2012, Bonnefond et al. 2011, Gondry et al. 2009). 
 
 
Figure 1. 2,5-DKP-derived natural products from Nocardiopsis sp. CMB-M0232 
presented in their hypothesized biosynthetic pathway: precursor, intermediate and 
product (left to right). Prenyl-derived groups are shown in yellow.   
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Figure 2.  A 2,5-diketopiperazine.  These are formed by the condensation of two α-amino 
acids, where R1 and R2 represent amino acid R groups.  
 
Nocardiopsis sp. produces three notable DKP natural products when 
fermented under high salinity conditions: cyclo(L-Trp-L-Trp) and nocardioazines 
A-B (Figure 1).  All three compounds share a common apparently tryptophan-
derived 2,5-DKP core. This leads to the hypothesis that cyclo(L-Trp-L-Trp) is the 
precursor, nocardioazine B an intermediate, and nocardioazine A the final 
product in the nocardioazine biosynthetic pathway (Figure 1). Many DKP natural 
products have been identified, but nocardioazines A-B are unique as the only 
known C3-prenylated DKPs from a prokaryote and the only indole-C3-normal 
prenylated DKP from any source, suggesting the presence of a unique and novel 
biosynthetic pathway from Nocardiopsis sp. Prenyl groups are branched 5-
carbon structures that are of considerable interest because of their prevalence 
amongst bioactive natural products (Raju et al. 2011). The unique prenylation of 
the nocardioazines strongly suggests that novel enzyme(s) carry out this 
biosynthetic transformation.  
Furthermore, Dr. Capon’s lab discovered that nocardioazine A functions 
as an anticancer agent (Raju et al. 2011). Many cancer cell lines become 
N
H
H
N O
O
R1
R2
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resistant to antitumor agents by overexpressing the ABC transporter, P-
glycoprotein (P-gp), which allows cells to eject the drug. Capon’s group found 
that nocardioazine A reverses drug resistance in colon cancer cells by acting as 
a noncytotoxic inhibitor of P-gp, preventing drugs from leaving the cell. 
Nocardioazine A proved to work as effectively as verapamil, a synthetic P-gp 
inhibitor (Raju et al. 2011).  
 The objective of this thesis study was to identify and characterize selected 
genes and corresponding enzymes involved in the biosynthesis of nocardioazine 
A from Nocardiopsis sp. CMB-M0232. Bioinformatics was used to identify 
candidate biosynthetic gene clusters with predicted roles in nocardioazine 
assembly. Selected genes within the clusters were characterized through 
heterologous expression and profiling of metabolites produced in vivo, as well as 
in vitro assays with purified pathway enzymes. These experiments established 
the enzymatic basis for assembly of cyclo(L-Trp-L-Trp) as the precursor of 
nocardioazine A-B and provided additional candidate biosynthetic enzymes for 
characterization in future studies.  
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Chapter II 
Characterization of two cyclodipeptide synthases from                       
Nocardiopsis sp. CMB-M0232 
 
Introduction 
An impressive number of naturally occurring, structurally diverse DKPs 
have been discovered, but their biosynthetic pathways often remain poorly 
understood (Giessen and Marahiel, 2014).  For years, a class of enzymes 
referred to as nonribosomal peptide synthetases (NRPSs) were recognized as 
catalysts for DKP assembly. NRPSs are highly studied, relatively massive (>100-
kDa) multimodular enzymes organized so that each module is involved in a 
single stage of synthesis beginning with a single amino acid modified one step at 
a time to produce a final peptide product. NRPSs are responsible for 
biosynthesis of the cyclized amino acid core of DKPs via direct, dedicated DKP-
yielding NRPSs or by prematurely releasing a DKP intermediate from the NRPS 
assembly line for a more complex peptide natural product (Giessen et al. 2013).  
In 2009, a new class of enzymes referred to as cyclodipeptide synthases 
(CDPSs) were first reported to also produce DKPs. CDPSs are unique in their 
small size (~30-kDa) relative to massive NRPSs that produce analogous 
molecules. Further, CDPSs use a mechanism that is distinct from what is used 
by NRPSs to form the peptide bond between two amino acids. This recently 
discovered family of enzymes does not employ several modules to activate and 
incorporate free amino acids.  Instead, CDPSs ‘hijack’ aminoacyl-tRNAs (aa-
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tRNAs) from the ribosomal machinery in primary metabolism to directly catalyze 
formation of peptide bonds to yield 2,5-DKPs (Figure 3) (Gondry et al. 2009, 
Belin et al. 2014, Moutiez et al. 2014).  By using aa-tRNAs as substrates, CDPSs 
bypass the amino acid activation step that NRPSs use and instead redirect 
amino acids away from the ribosome, linking primary and secondary metabolism 
(Giessen and Marahiel, 2012, Bonnefond et al. 2011, Giessen and Marahiel, 
2014).   
 
Figure 3. CDPSs are a relatively newly described enzyme family that employs 
aminoacyl-tRNAs as substrates for 2,5-DKP assembly.  R refers to an amino acid R 
group.  
 
To date, over 150 putative CDPS enzymes are logged in the GenBank 
database, but less than 12 have been biochemically characterized (Giessen and 
Marahiel, 2014). Thus, much remains to be known about this apparently common 
biosynthetic enzyme class. Protein sequence comparisons of biochemically 
characterized CDPSs reveal varying degrees of identity ranging from 19-70%; 
only 8 residues are conserved across all functionally characterized CDPSs and 
no consensus sequences are noted for these enzymes (Figure 5). Despite 
variation in protein sequences, x-ray structures of the three crystallized CDPSs 
CDPS 
N
H
H
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O
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aminoacyl-tRNA 2,5-DKP 
R 
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superimpose relatively well, providing evidence for conserved amino acid 
residues appearing in the active site and playing critical roles in the substrate 
specificity of the enzymes. CDPSs generally exhibit promiscuity with regard to 
aa-tRNA substrates, and most produce several 2,5-DKP products. Although most 
CDPSs can produce several DKPs, they tend to preferentially synthesize a single 
DKP over other products. Single point mutations in albC from Streptomyces 
noursei were sufficient to alter the specificity of the enzyme and revealed the 
one-at-a-time incorporation of aminoacyl charged-tRNAs in the active site 
(Moutiez et al. 2014).  Moutiez et al. (2014) also recently unveiled the process of 
how CDPSs catalyze reactions with aa-tRNA substrates using as a sequential 
ping-pong mechanism (Figure 4).   
 
 
	   14	  
 
Figure 4. Overview of the mechanism employed by cyclodipeptide synthases to catalyze 
the production of DKPs. (a) Activated aa-tRNA’s are sequestered from primary 
metabolism. (b) Binding of the first aminoacyl moiety from an aa-tRNA to the CDPS’s 
serine active site. (c) The first aminoacyl group forms a peptide bond with an aminoacyl 
moiety from a second aa-tRNA substrate. (d) The resulting dipeptidyl intermediate 
undergoes intramolecular peptide bond formation to close the DKP ring and releases it 
from the active site.  
 
Generally, prokaryotic CDPSs produce DKPs that incorporate 
phenylalanine, leucine, tyrosine and/or methionine. Only one CDPS from 
eukaryotic origin has been identified and that CDPS, Nvec_CDPS2, is able to 
incorporate the same four amino acids as well as tryptophan. DKPs that 
incorporate tryptophan are recognized as promising bioactive metabolites and 
are relatively common molecules despite the scarce number of identified CDPSs 
that incorporate tryptophan. Thus, this has left open the question of how living 
things yield the wealth of observed Trp-containing DKPs. Recently, Giessen et al. 
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(2013) characterized Amir_4627, a CDPS from Actinosynnema mirum, and found 
this enzyme as the first to catalyze the production of cyclo(L-Trp-L-Trp). This 
discovery also provided the first substrate specific CDPS and the first CDPS 
identified from prokaryotic origin to catalyze formation of a Trp-containing DKP.  
In this chapter we aim to identify biosynthetic genes and corresponding 
enzymes from the draft genome of Nocardiopsis sp. CMB-M0232 with 
hypothesized roles in the first step of nocardioazine A biosynthesis, the catalysis 
of cyclo(L-Trp-L-Trp) assembly. It is understood that genes involved in the 
production of a specific secondary metabolite are generally clustered in the 
genomes of bacteria; this facilitates the identification of biosynthetic pathways 
(Giessen and Marahiel, 2012).  By identifying the enzyme(s) responsible for the 
production of cyclo(L-Trp-L-Trp), we may locate other genes involved in 
nocardioazine A biosynthesis nearby and thus gain access to the entire 
biosynthetic pathway.  
 
Methods 
Genome sequencing and bioinformatics analyses of Nocardiopsis sp. draft 
genome to locate candidate enzymes from the nocardioazine A 
biosynthetic pathway 
A clone library of Nocardiopsis sp. CMB-M0232 genomic DNA was 
created according to procedures described in Bis et al. (2015). Sequencing of 
Nocardiopsis sp. CMB-M0232 gDNA was performed by Cofactor Genomics (St. 
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Louis, MO) using Illumina with paired-end 80 bp reads and 454 with single end 
400 bp reads. BLASTP was used to analyze ORFs for homology to nonribosomal 
peptide synthases and cyclodipeptide synthases, putative enzymes in cyclo(L-
Trp-L-Trp) biosynthesis. Geneious Bioinformatics Software (Biomatters) and 
BLASTP were used to compare protein sequence homology between CDPSs 
(ClustalW).  The phylogenetic tree was created using Geneious Treebuilder with 
no outgroup.  
 
Generation of constructs for recombinant expression of Nocardiopsis sp. 
CDPS genes, nozA and ncdA, in E. coli   
The genes encoding NozA and NcdA from Nocardiopsis sp. draft genome 
sequence contig 557 and contig 96, respectively, were codon optimized for 
expression in E. coli and were cloned into the pMA-T vector by GeneArt (Life 
Technologies) (Appendix A-B). The pMA-T/nozA and pMA-T/ncdA constructs 
were introduced into E. coli JM109 by heat shock (Green and Sambrook, 2012). 
Isolated colonies were used to inoculate LB media (10 g/L peptone, 5 g/L yeast 
extract, 10 g/L sodium chloride) supplemented with ampicillin (100 µg/mL) and 
were cultured at 37 °C and 200 rpm overnight. Plasmid DNA was purified from 
the cultures using a Qiagen Miniprep Kit and isolated DNA was then digested in 
a reaction mixture containing 1.0 µL (~1 µg) of the purified plasmid DNA (pMA-
T/nozA or pMA-T/ncdA), 4.0 µL of 10X Thermo FastDigest Green Buffer, 2.0 µL 
of restriction enzymes (Thermo Scientific) and 31.0 µL of molecular biology grade 
water to prepare the CDPS genes for ligation into expression vectors. For 
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purposes of in vivo characterization of enzyme function, both nozA and ncdA 
were introduced into pQE30 expression vectors and E. coli M15[pREP4] via 
protocols that follow. The expression of NcdA was too low in pQE30 for the in 
vitro experiments, so the following methods were used to instead introduce ncdA 
into pET30a(+) expression vector and E. coli BL21 (DE3).  
The pMA-T/nozA was digested with SacI and HindIII and pMA-T/ncdA was 
digested with Ndel and HindIII. The reactions were incubated at 37 °C for 1 hour 
followed by heat inactivation at 70 °C for 10 minutes. Expression vectors, pQE30 
(Qiagen) and pET30a(+) (Novagen), were digested in reactions containing 22 µL 
of molecular biology grade water, 4 µL of 10X FastDigest Green Buffer, 10 µL 
(~1 ug) of purified plasmid (pQE30 or pET30a(+)) and 2 of µL of each restriction 
enzyme.  The reactions incubated at 37 °C for 45 minutes followed by heat 
inactivation at 70 °C for 10 minutes. The digests were purified using the Qiagen 
QIAquick PCR Cleanup Kit and then subjected to dephosphorylation in reactions 
containing 20 µL of molecular biology grade water, 4 µL of Alkaline Phosphatase 
10X Buffer (Promega), 15 µL (~15 µg) of restriction digested vector and 1 µL of 
Calf Intestinal Alkaline Phosphatase (Promega).  The reactions were incubated 
at 37 °C for 1 hour followed by heat inactivation at 70 °C for 15 minutes. Digested 
CDPSs and expression vectors were verified by agarose gel electrophoresis and 
the appropriate sized DNA fragments were cut from the gels and purified using 
the Qiagen QIAquick Gel Extraction Kit.   
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A ligation reaction to anneal the synthetic nozA gene with pQE30 
contained 50 ng of digested pQE30, 37.5 ng of NozA insert DNA, 0.5 µL of 10X 
T4 DNA Ligase Buffer (Thermo Scientific), 0.5 µL of T4 DNA Ligase (Thermo 
Scientific) and sufficient molecular biology grade water to yield a final volume of 5 
µL. The ligations were incubated overnight at 4 °C.  The same reaction was set 
up to ligate the synthetic ncdA gene with the pET30a(+). The pQE30/nozA 
construct was propagated in E. coli JM109 and transformed into E. coli 
M15[pREP4] cells using standard heat shock methods (Green and Sambrook, 
2012). The pET30a(+)/ncdA construct was propagated in E. coli JM109 and then 
transformed into E. coli BL21 (DE3) via heat shock. The constructs were 
confirmed by DNA sequencing (Operon).  As no biosynthetic gene controls, E. 
coli M15[pREP4] and E. coli BL21 (DE3) were transformed with pQE30 and 
pET30a(+) plasmid vector, respectively. 
 
In vivo characterization of functions of NozA and NcdA  
The pQE30/nozA construct in E. coli M15[pREP4] was cultured in 10 mL 
LB broth supplemented with ampicillin (100 µg/mL) and kanamycin (25 µg/mL). 
The pET30a(+)/ncdA construct in E. coli BL21 (DE3) was cultured in 10 mL LB 
broth supplemented with kanamycin (25 µg/mL).  Control E. coli M15[pREP4] 
pQE30 and E. coli BL21 (DE3) pET30a(+) containing no biosynthetic genes were 
cultured equivalently to treatments.  All treatment and control cultures were 
incubated at 37 °C and 200 rpm until an optical density (OD600) of 0.4 was 
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reached. Aliquots of each culture (500 µL) were taken to analyze protein 
expression prior to induction. The remaining ~9.5 mL cultures were induced with 
a final concentration of 1 mM IPTG and were incubated at 19 °C and 240 rpm for 
an additional 19 hours. Following incubation, aliquots of each culture (500 µL) 
were taken to analyze protein expression following induction. The remaining ~9.0 
mL cultures were centrifuged at 6,000 rpm for 10 minute and the supernatants 
were set aside for metabolite profiling by HPLC (described below). 
 Cell pellets (corresponding to 500 µL culture volume) taken before and 
after induction with IPTG were subjected to -80 °C for 1 hour to facilitate cell lysis 
and then resuspended in 200 µL of B-PER (Bacterial Protein Extraction Reagent, 
Thermo Scientific) with lysozyme (1 mg/mL). The homogenates were incubated 
in a 30 °C water bath for 30 minutes and then centrifuged at 13,000 rpm for 6 
minutes.  Supernatant (20 µL) from each sample was combined with 4X LDS 
Non-Reducing Sample Buffer (Thermo Scientific) and subjected to SDS-PAGE to 
evaluate expression of recombinant NozA and NcdA. 
For analysis of the DKP metabolite profiles from treatment and control 
cultures, supernatants (~9 mL) were filter sterilized (0.2 uM cellulose acetate 
membrane) into a scintillation vial and dried using a speedvac concentrator 
(Savant ISS1100, Thermo Scientific) overnight. The dried supernatants were 
resuspended in 500 µL MilliQ water and were transferred to HPLC vials. HPLC 
was conducted using an Aligent 1100 HPLC system with a ZORBAX SB-C18 
column (4.6 x 150 mm, particle size: 5 µm, pore size of 110 Å). A flow rate of 0.6 
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mL/min was used, with solvent A consisting of MilliQ water, solvent C consisting 
of acetonitrile and a linear gradient of 0 to 95% solvent C over 50 minutes 
following a 3 minute hold at 100 % solvent A. Synthetic cyclo(L-Trp-L-Trp) (0.2 
mg/mL) was run as a positive control and provided by Alqahtani et al. (2015). 
Metabolite profiles were compared using ChemStation (Agilent). 
 
Site directed mutagenesis of NozA at residues conserved among NozA, 
NcdA and Amir_4627 
NozA was mutated at several residues unique to L-tryptophan-specific 
CDPSs to determine whether the residues played a role in catalysis of cyclo(L-
Trp-L-Trp) formation. Six primer sets were designed with the goal of yielding 
single and double amino acid point mutations (S36A, L131R, S198L, N114R, 
N114A, V111R+N114A) by PCR mutagenesis. The PCRs contained 17.9 of µL 
molecular biology grade water, 0.1 µL of each forward and reverse primer 
(Appendix C, SDM_Mutant_F/R) (0.5 µM final concentration), 5 µL of 5X Phusion 
GC Buffer (Thermo Scientific), 0.5 µL of High Fidelity dNTPs (Roche, 10 mM final 
concentration), 0.75 µL of DMSO, 0.5 µL of template gDNA (0.4 µg) 
(pQE30/nozA) and 0.125 µL of Phusion DNA Polymerase (Thermo Scientific). 
The PCRs ran for an initial denaturation of 98 °C for 30 s, 25 cycles of 98 °C for 
10 s and 72 °C for 60 s, and a final extension of 72 °C for 5 min with a hold at 4 
°C. The PCR products were verified for size (4.1 Kb) by agarose gel 
electrophoresis and the appropriate sized DNA fragments were cut from the gels 
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and purified using the Qiagen QIAquick Gel Extraction Kit.  The mutated 
constructs were ligated on themselves in a reaction containing 2.5 µL (~50 ng) of 
the gel purified constructs, 3 µL of 2X DNA ligase buffer and 0.5 µL of T4 DNA 
ligase (Thermo Scientific) and were incubated at 25 °C for 8 min. The cyclized 
constructs were introduced into E. coli JM109 for propagation, purified by 
miniprep and then transformed into E. coli M15[pREP4] by heat shock (Green 
and Sambrook, 2012) and incubated on LB agar with ampicillin (100 µg/mL) and 
kanamycin (25 µg/mL) at 37 °C overnight. The pQE30 vector containing no 
biosynthetic genes served as the negative control and pQE30/nozA served as 
the positive control.  
Control constructs were transformed in E. coli M15[pREP4] and were 
treated identically to the mutated constructs in E. coli M15[pREP4]. In order to 
run duplicate experiments, two colonies from each agar plate (E. coli 
M15[pREP4] pQE30/nozA-S36A, -L131R, -S198L, -N114R, -N114A, -
V111R+N114A and controls) were inoculated in 10 mL LB broth with ampicillin 
(100 µg/mL) and kanamycin (25 µg/mL) and were incubated at 37 °C and 200 
rpm until an optical density (OD600) of 0.4 was reached. The cultures were 
induced with a final concentration of 1 mM IPTG and were incubated for an 
additional 20 hours at 19 °C and 240 rpm.  Following incubation, the optical 
density (OD600) was measured to ensure the site directed mutations did not 
interfere with E. coli growth. The cultures were centrifuged at 6,000 rpm for 10 
minutes and the supernatants were filtered through a 0.2 µM cellulose acetate 
membrane. For LC/MS analysis, 450 µL of the supernatants were combined with 
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50 µL of a synthetic cyclo-3-methyl-L-Trp-N1’-methyl-L-Trp DKP internal 
standard synthesized by Alqahtani et al. (2015). The remaining supernatants 
were dried using a speedvac concentrator (Savant ISS1100, Thermo Scientific) 
overnight, resolubilized in 500 µL MilliQ water and subjected to analytical HPLC 
as described above.  
 
Expression and purification of NozA  
From an overnight culture of E. coli M15[pREP4] transformed with 
pQE30/nozA, 1 mL was used to inoculate 500 mL LB medium supplemented with 
ampicillin (100 µg/mL) and kanamycin (25 µg/mL). The culture was incubated for 
4 hours at 37 °C and 200 rpm until an optical density (OD600) of ~0.4 was 
reached. The culture was induced with a final concentration of 1 mM IPTG and 
incubated for an additional 16 hours at 16 °C and 240 rpm. Cells were harvested 
by centrifugation (6,000 rpm, 4°C), resuspended in 16 mL lysis buffer (100 mM 
Tris HCl, 150 mM NaCl, 5% glycerol, 2 mM DTT, pH 8) and lysozyme (20 mg) 
and were incubated at -20 °C and 200 rpm for 30 minutes. Following incubation, 
the suspension was sonicated (Branson Digital Sonifier) at 60% amplitude for 2 
minutes (1 s pulse:10 s rest).  Cell debris was removed by centrifugation (12,000 
rpm, 4 °C) and the soluble lysate was filtered through a 0.45 µM cellulose acetate 
membrane (Corning). The lysate, containing soluble proteins, was combined with 
3 mL of HisPur Ni-NTA Resin (Thermo Scientific), spiked with a final 
concentration of 5 mM imidazole and incubated at 4 °C and 200 rpm for 30 
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minutes. Lysis buffer with increasing concentrations of imidazole (10 mM, 50 
mM, 200 mM and 500 mM) was run through the column and collected. A sample 
(20 µL) of each Ni-column fraction was combined with 3 µL 4X LDS Non-
Reducing Sample Buffer (Thermo Scientific), boiled briefly and loaded into a 12% 
Precise Protein Gel (Thermo Scientific) along with PageRuler Plus Prestained 
Protein Ladder (Life Technologies). The gel was stained with Imperial Protein 
Stain (Thermo Scientific) for 30 minutes and destained in Milli-Q water. The Ni-
column fractions containing NozA (~28-kDa) were concentrated using an Amicon 
Ultra Centrifugal Filter Device with a 10,000 MWCO (Millipore) to a final volume 
of 500 µL and resuspended in 5 mL Buffer A (100 mM Tris HCl, 50 mM NaCl, 5% 
glycerol, 2 mM DTT, pH 8) for further purification via FPLC. The sample was 
loaded onto a HiTrap Q FF. (5x5 mL) anion exchange column (GE Healthcare) 
that was pre-equilibriated with buffer A and the protein was eluted with a gradient 
of 0 to 100% buffer B (100 mM Tris HCl, 1 M NaCl, 5% glycerol, 2 mM DTT, pH 
8) for 50 mL at a rate of 1 mL/min. Protein elution was monitored at 280 nm and 
all fractions containing detectable protein were analyzed via SDS-PAGE as 
described previously. The fractions containing NozA (~28-kDa) were 
concentrated and the buffer was exchanged to assay buffer (50 mM Tris HCl, 
300 mM NaCl, pH 8) using an Amicon Ultra Centrifugal Filter Device with a 
10,000 MWCO.  The purified protein was stored on ice while in vitro assays were 
prepared.   
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Expression and purification of NcdA 
A -80 °C freezer stock of E. coli BL21 (DE3) transformed with 
pET30a(+)/ncdA was streaked onto LB agar supplemented with kanamycin (25 
µg/mL) and incubated overnight at 37 °C.  LB media (5 mL) supplemented with 
kanamycin (25 µg/mL) was inoculated with an isolated colony and grown at 37 °C 
and 200 rpm for ~4 hours.  Following incubation, 1 L of LB broth with kanamycin 
was inoculated with 1 mL of this starter culture and grown at 37 °C and 200 rpm 
until an optical density (OD600) of ~0.4 was reached. The culture was induced 
with a final concentration of 1 mM IPTG and incubated for an additional 16 hours 
at 19 °C and 240 rpm. The cells were harvested by centrifugation (6,000 rpm, 
4°C) and were resuspended in 30 mL lysis buffer with lysozyme (37.5 mg).  The 
30 mL suspension was split between two 50 mL falcon tubes and each aliquot 
(15 mL) was sonicated at 60% amplitude for 2 minutes (1 s pulse:10 s rest) on 
ice. Cell debris was removed by centrifugation (12,000 rpm, 4 °C) and the soluble 
lysate was filtered through a 0.45 µM cellulose acetate membrane (Corning).  
The lysate was combined with 3mL HisPur Ni-NTA Resin (Thermo Scientific), 
spiked with a final concentration of 5 mM imidazole and incubated at 4 °C and 
200 rpm for 30 minutes. Lysis buffer with increasing concentrations of imidazole 
(10 mM, 50 mM, 100 mM x 2, 200 mM x 2 and 500 mM) was run through the 
column and collected. An aliquot of each Ni-column fraction was analyzed by 
SDS-PAGE as described previously.  The Ni-column fractions containing NcdA 
(~29-kDa) were concentrated using an Amicon Ultra Centrifugal Filter Device 
with a 10,000 MWCO (Millipore) to a final volume of 500 µL and resuspended in 
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5 mL Buffer A (100 mM Tris HCl, 50 mM NaCl, 5% glycerol, 2 mM DTT, pH 7.5) 
for further purification via fast protein liquid chromatography (FPLC). The sample 
was loaded onto a HiTrap Q FF. (5x5 mL) anion exchange column (GE 
Healthcare) pre-equilibriated with buffer A and the protein was eluted with a 
gradient of 0 to 30% buffer B (100 mM Tris HCl, 1 M NaCl, 5% glycerol, 2 mM 
DTT, pH 7.5) for 50 mL at a rate of 1 mL/min. Protein elution was monitored at 
280 nm and all fractions containing detectable protein were analyzed via SDS-
PAGE gel as described previously. The fractions containing NcdA (~29 kDa) 
were concentrated and the buffer was exchanged to assay buffer (50 mM Tris 
HCl, 300 mM NaCl, pH 8) using an Amicon Ultra Centrifugal Filter Device with a 
10,000 MWCO.  The purified protein was stored in 1 mM TCEP and 5% glycerol 
at -80 °C until in vitro enzyme assays.  
 
In vitro characterization of NozA and NcdA functions and substrate 
specificity 
To evaluate the function and substrate specificity of the Nocardiopsis 
CDPSs in vitro, 100 µL assays containing purified recombinant NozA and NcdA 
were incubated with tRNA from E. coli (50 µM, Sigma-Aldrich), E. coli aminoacyl-
tRNA synthetase mix from E. coli (250 units, Sigma, Aldrich), L-Tryptophan (1 
mM), ATP (5 mM), MgCl2 (10 mM), KCl (30 mM) and DTT (2 mM) in Tris buffer 
(50 mM Tris HCl, 300 mM NaCl, pH 8). Control assays that (1) lacked enzyme, 
(2) lacked amino acids, (3) lacked tRNA and/or (4) lacked aminoacyl-tRNA 
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synthetase mix were run alongside treatments. All assays were set up at least in 
duplicate. All assay components other than the CDPS enzyme were pre-
incubated at 37 °C for 20 minutes to allow charging of the tRNA with tryptophan. 
NozA assays were set up the same day as purification, so the enzyme was 
added to the pre-incubated assay directly following purification. Purified NcdA 
was thawed from -80 °C by incubation in 30 °C water prior to addition to assays.  
To evaluate substrate specificity of NozA and NcdA, in vitro assays 
identical to those described above were designed with alternative aromatic amino 
acids (L-phenylalanine and L-tyrosine, 1 mM). Treatment and control assays 
were incubated overnight at 37 °C.   
The reactions were stopped by the addition of 5 µL of trichloroacetic acid 
(100% w/v) and centrifugation at 13,000 rpm for 30 minutes to precipitate all 
proteins. The supernatants (90 µL) were transferred to HPLC vials and combined 
with 10 µL of methyl-cyclo(L-Trp-L-Trp) (1 µM), which served as an internal 
standard for quantification via  HPLC and LC/MS as described previously.  
 
Results and Discussion 
Nocardioazine biosynthetic gene clusters hypothesized via bioinformatics 
analyses of Nocardiopsis sp. draft genome 
Sequencing of Nocardiopsis sp. CMB-M0232 genomic DNA yielded a ~6.4 
Mbp draft of the genome, from which over ~5500 open reading frames (ORFs) 
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were predicted using GeneMark (Besemer et al. 2001). These included 11 
putative biosynthetic gene clusters, as predicted by AntiSmash (Weber et al. 
2015). Analysis of the putative biosynthetic gene clusters by Basic Local 
Alignment Search Tool for proteins (BLASTP) revealed two candidate ORFs with 
similarity to nonribosomal peptide synthetases (NRPSs) and two with similarity to 
cyclodipeptide synthases (CDPSs). Both classes of enzymes have been 
previously found to be capable of catalyzing the formation of the DKP 
backbones, suggesting these enzymes might play roles in assembly of the 
predicted cyclo(L-Trp-L-Trp) precursor leading to nocardioazines A-B (Figure 2).  
Further bioinformatics analyses of the adenylation domains from the putative 
NRPSs revealed that none of the NRPSs were likely to incorporate two 
tryptophan substrates. Additionally, genes identified upstream and downstream 
from the putative NRPS are similar to those found in a hybrid polyketide 
synthase-nonribosomal peptide synthetase biosynthetic pathway known to 
produce natural products other than prenylated diketopiperazines. Outside the 
scope of this thesis, one of these NRPSs was found to play a role in nocardiopsin 
assembly (Bis et al. 2015). 
 
NozA and NcdA are putative cyclodipeptide synthases with homology to 
Amir_4627, revealed via bioinformatics  
The putative CDPSs NozA and NcdA, identified by bioinformatics 
analyses are the most likely candidates for production of the cyclo(L-Trp-L-Trp) 
DKP precursor in nocardioazine biosynthesis. Comparison of NozA and NcdA to 
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other known CDPSs revealed both enzymes share all 8 residues conserved 
among biochemically characterized CDPSs (Figure 5) (Moutiez et al. 2014). Of 
the conserved residues, serine-36 is conserved among the active sites and is 
necessary for recognition and covalent linkage of CDPSs to the aminoacyl group 
from amioacyl-charged tRNA substrates (Moutiez et al. 2014).  
 
 
Figure 5.  Alignment of CDPSs NozA and NcdA encoded by Nocardiopsis sp. CMB-
M0232 with all biochemically characterized CDPSs. Secondary structures (grey) are 
based upon features conserved for the structures of crystallized CDPSs AlbC, Rv2275, 
and YvmC_lic.  Residues conserved among all CDPSs are indicated with a *; these 
include the serine active site (red).  For crystallized CDPSs, basic residues from the α4 
helix (blue) play roles in recognition of the first tRNA group.  Residues in green and 
yellow comprise the binding pocket of the first and second aminoacyl groups, 
respectively, for indicated enzymes. Residues in pink refer to those specific to NozA, 
NcdA and Amir_4627, the only substrate specific CDPSs the only ones known to 
catalyze assembly of cyclo(L-Trp-L-Trp). 
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Phylogenetic analysis of 11 previously characterized CDPSs based on 
protein sequence homology organized the enzymes into three monophyletic 
groups: one group incorporating aromatic amino acids, a second group 
representative of the only CDPS from eukaryotic origin, and a third group 
incorporating non-aromatic amino acids (Figure 6).  NozA and NcdA were both 
most closely related to CDPSs that incorporate aromatic substrates.  This 
comparison also revealed that NozA and NcdA share 35 and 67% identity, 
respectively, to Amir_4627 from Actinosynnema mirum, the only characterized 
CDPS that incorporates two Trp residues (Figure 6). Amir_4627 is also the only 
functionally characterized CDPS with specificity for one substrate. This 
relatedness is suggestive that NcdA (67% ID to Amir_4627) may exhibit similar 
activity to Amir_4627.  The sequence of NozA, more distantly related to 
Amir_4627 (35% ID), is not as suggestive of biosynthesis of cyclo(L-Trp-L-Trp), 
but is likely to incorporate aromatic amino acids based on its phylogenetic 
relationship to other CDPSs catalyzing formation of aromatic DKPs (Figure 6). 
Based on these bioinformatics predictions, characterization of both NozA and 
NcdA was then undertaken to reveal the substrate specificity of both enzymes 
and whether they may be involved in nocardioazine A biosynthesis by catalyzing 
the production of the cyclo(L-Trp-L-Trp) precursor.  
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Figure 6.  Phylogenetic tree of NcdA and NozA relative to all previously characterized 
CDPSs. The CDPSs organized into three monophyletic groups: (a) CDPSs that 
incorporate aromatic amino acids, (b) the single characterized CDPS from eukaryotic 
origin, and (c) CDPSs that incorporate non-aromatic amino acids. The only previously 
characterized CDPS that yielded cyclo(L-Trp-L-Trp), Amir_4627, is shown in purple. 
Amir_4627 and NcdA (top blue box) share 67% identity. Amir_4627 and NozA (bottom 
blue box) share 35% identity. Enzymes characterized in this current study are 
highlighted in blue. The only previously characterized CDPS that yielded cyclo(L-Trp-L-
Trp) is shown in purple. The DKP product is shown with one-letter abbreviations for L-
amino acids, e.g. cyclo(L-Trp-L-Trp) is listed as cWW. Most CDPSs are promiscuous; 
only the product formed in greatest yield is indicated. The Nvec-CDPS2 product is 
shown as cWX, since multiple amino acids were non-preferentially incorporated as the 
second residue of the DKP. Protein accession numbers are listed in the appendix 
(Appendix D). 
 
 
Nocardiopsis sp. CMB-M0232  NcdA  c(??) 
Staphylococcus haemolyticus  pSHaeC06  c(LF) 
Bacillus licheniformis  YvmC-thu  c(LL)   
Photorhabdus luminescens laumondii  Plu0297 c(LL)  
Corynebacterium jeikeium  Jk0923  c(LL) 
Streptomyces noursei  AlbC  c(LF) 
Nocardiopsis dassonvillei  Ndas_1148  c(FY) 
Actinosynnema mirum  Amir_4627  c(WW) 
Mycobacterium tuberculosis  Rv2275  c(YY) 
Nocardiopsis sp. CMB-M0232  NozA  c(??) 
Bacillus licheniformis  YvmC-sub  c(LL)   
Bacillus licheniformis  YvmC-lic  c(LL)   
Nematostella vectensis Nvec-CDPS2 c(WX) 
a)#
b)#
c)#
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Recombinant expression of NozA and NcdA in E. coli 
In order to produce NozA and NcdA in greater quantities than what is 
provided by the native organism (Nocardiopsis sp.) and to facilitate enzyme 
purification through tagging with an affinity label (e.g. hexahistidine), the 
enzymes were recombinantly expressed in E. coli.  Codon optimized nozA was 
introduced into the pQE30 plasmid vector. Codon optimized ncdA was introduced 
into plasmid vector pQE30 for in vivo characterization and pET30a(+) for in vitro 
characterization. The constructs were then introduced into E. coli. Agarose gel 
electrophoresis confirmed E. coli M15[pREP4] pQE30/nozA, E. coli M15[pREP4] 
pQE30/ncdA, and E. coli BL21 (DE3) pET30a(+)/ncdA were successfully 
constructed, showing both the vector and insert were present following 
purification of plasmid DNA and restriction digest (Figure 7). This finding was 
further confirmed by DNA sequencing, which revealed a perfect match between 
the expected and experimental DNA sequence of gene inserts.  
 
 
 
 
 
 
	   32	  
a)  b)  
Figure 7.  Verification of assembly of constructs for E. coli expression of nozA and ncdA. 
(a) Lane 1 contains GeneRuler 1 kb Plus DNA Ladder, lane 2 contains nozA (711 bp) 
digested from pQE30 plasmid vector (3.4-Kb) and lane 3 contains ncdA (753 bp) 
digested from pQE30 plasmid vector (3.4-Kb). (b) Lane 1 contains GeneRuler 1 kb Plus 
Ladder and lane 2 contains ncdA (753 bp) digested from pET30a(+) (5.4-Kb).  
 
E. coli pQE30/nozA and pQE30/ncdA were induced with IPTG to 
upregulate expression of the genes encoding NozA and NcdA. The optical 
density (OD600) measured before (~0.4) and after induction (~1.0) confirmed 
uniform growth among all treatment (carrying nozA or ncdA) and control cultures 
(carrying vector without biosynthetic genes). SDS-PAGE analysis of induced 
control and both uninduced and induced treatment soluble lysates suggested 
successful overexpression of both CDPSs as soluble proteins upon induction 
with IPTG (Figure 8). With this confirmation of the expression of both NozA and 
NcdA, the catalytic function of these enzymes was next probed.  
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Figure 8.  SDS-PAGE verifying the overexpression of NozA and NcdA in the soluble 
lysates of recombinant E. coli upon induction with IPTG.  Lane 1 contains BenchMark 
Pre-Stained Protein Ladder (Life Technologies) and lane 2 contains soluble proteins 
from the induced E. coli M15[pREP4] pQE30 vector control, containing no biosynthetic 
genes. Lane 3 contains soluble proteins from the uninduced E. coli M15[pREP4] pQE30 
vector control, containing no biosynthetic genes. Lanes 4-5 contain soluble proteins from 
induced and uninduced M15[pREP4] pQE30/ncdA, respectively. Lanes 6-7 contain 
soluble proteins from induced and uninduced M15[pREP4] pQE30/nozA, respectively.  
Overexpression of proteins in observed in treatment lanes lanes 4 and 6 at the correct 
NcdA and NozA respective molecular weights of 29- and 28-kDa, respectively.  
 
Characterization of the functions of recombinantly expressed NozA and 
NcdA in vivo 
Metabolite profiles of supernatants from induced treatment and control 
cultures were compared using HPLC to determine the presence of cyclo(L-Trp-L-
Trp) upon expression of NozA and NcdA in vivo. When compared to the empty 
vector control, recombinant E. coli expressing NozA or NcdA produced a unique 
HPLC UV signal (~23.7 min), matching the retention time of the signal created by 
a synthetic cyclo(L-Trp-L-Trp) standard (Figure 9). High resolution LC/MS 
analyses of the metabolites revealed almost identical molecular weights between 
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the metabolites and synthetic standard, further supporting that both NozA and 
NcdA catalyze the production of cyclo(L-Trp-L-Trp), the putative precursor in 
nocardioazine biosythesis. The observed in vivo [M+Na]+ m/z for synthetic 
cyclo(L-Trp-L-Trp) was 395.1472, for NozA cyclo(L-Trp-L-Trp) was 395.1470, 
and for NcdA cyclo(L-Trp-L-Trp) was  395.1474.   
 
 
Figure 9.  HPLC metabolite profiles for supernatants from IPTG-induced E. coli cultures 
pQE30/nozA or pQE30/ncdA relative to control cultures featuring empty pQE30 vector.  
A distinct signal at 23.7 minutes was observed in supernatants from treatment E. coli but 
was absent from control E. coli carrying empty pQE30 vector. The retention time of the 
metabolite matched that of synthetic cyclo(L-Trp-L-Trp) standard, supporting that both 
NozA and NcdA are able to catalyze cyclo(L-Trp-L-Trp) assembly. Chromatograms show 
absorbance at 280 nm.          
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Probing the roles of conserved amino acid residues in catalysis by NozA 
NozA, NcdA, and Amir_4627 are unique as the only CDPSs known to 
catalyze formation of cyclo(L-Trp-L-Trp). Several residues conserved between 
the protein sequences of NozA, NcdA and Amir_4627 were identified and 
mutated in NozA using PCR-targeted site directed mutagenesis in order to 
determine whether or not the conserved residues played a role in the enzyme’s 
preference for tryptophan. Furthermore, a residue identified in AlbC proven to 
play a critical role in the substrate preference of the enzyme was mutated in 
NozA via PCR-targeted site directed mutagenesis to determine if changing that 
residue would alter the substrate preference of NozA. The serine-36 residue 
conserved among the functionally characterized CDPSs was also mutated in 
NozA to determine whether that residue played a role in the active site of the 
enzyme.  
The optical density (OD600) measured before (~0.4) and after induction 
with IPTG (~1.0) confirmed uniform growth among control (E. coli M15[pREP4] 
carrying NozA with no site directed mutations) and treatment cultures (E. coli 
M15[pREP4] carrying NozA with mutated residues). SDS-PAGE analysis of 
treatment and control culture lysates verified uniform protein expression among 
all cultures suggesting that nozA site directed mutations did not interfere with E. 
coli growth (Figure 10).  
Metabolite profiles of NozA site directed mutagens alongside controls 
analyzed by HPLC revealed production of cyclo(L-Trp-L-Trp) was abolished upon 
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mutation of the serine residue to an alanine in NozA’s active site (S36A).  These 
data imply that serine-36 plays an essential role in NozA catalysis and suggest 
that NozA employs a catalytic mechanism analogous to that recently unveiled for 
AlbC, (Moutiez et al. 2014) a CDPS 33% homologous to NozA.  During the first 
step of AlbC catalysis, the aminoacyl moiety from aa-tRNA is transferred onto the 
serine active site.  This aminoacyl group forms a peptide bond with an aminoacyl 
moiety donated from a second aa-tRNA substrate, and the resulting dipeptidyl 
intermediate then undergoes intramolecular peptide bond formation to close the 
DKP ring and concomitantly release from the active site.  
The other mutations did not alter the enzyme’s ability to catalyze the 
production of cyclo(L-Trp-L-Trp), suggesting those conserved residues are not 
critical in the enzyme’s substrate specificity (Figure 11). Additionally, production 
of alternative cyclodipeptide metabolites due to the mutations made to NozA 
were not observed.  
 
 
 
	   37	  
 
Figure 10.  SDS-PAGE verifying uniform protein expression among E. coli M15[pREP4] 
pQE30 carrying nozA with and without site directed mutations.  Lane 1 contains 
PageRuler Plus Prestained Protein Ladder, lane 2 contains pQE30 carrying no 
biosynthetic genes, lane 3 contains pQE30/nozA (no mutations), lane 4 contains 
pQE30/nozA-S36A, lane 5 contains pQE30/nozA-L131R, lane 6 contains pQE30/nozA-
S198L, lane 7 contains pQE30/nozA-N114R, lane 8 contains pQE30/nozA-N114A and 
lane 9 contains pQE30/nozA-V111R+N114A. The optical density (OD600) following 
fermentation with IPTG was ~1.0 for each culture, suggesting that the nozA site directed 
mutations did not interfere with E. coli growth.  
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Figure 11.  HPLC metabolite profiles for E. coli M15[pREP4] producing NozA site 
directed mutagens. A distinct signal at 23.7 minutes, indicating cyclo(L-Trp-L-Trp) 
production, was observed in the supernatants from all treatments and controls except 
the empty vector control carrying no biosynthetic genes and the S36A mutant, where the 
serine active site residue was replaced with alanine. This confirmed the critical role of 
the serine-36 residue for the catalytic function of NozA. Chromatograms show 
absorbance at 280 nm.          
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Characterization of the function and substrate preferences of purified 
recombinant NozA and NcdA in vitro 
By exploiting the hexahistidine tags incorporated into NozA and NcdA by 
the expression plasmids, the purification of both enzymes began with standard 
Ni-affinity chromatography (Figure 12, a-b). Subsequent purification by anion 
exchange FPLC resulted in >90% pure NozA and NcdA for in vitro analysis of 
enzyme functions and substrate preferences (Figure 12, c-d).  
Previously characterized CDPSs were found to use aminoacyl-tRNAs as 
substrates for the catalysis of 2,5-DKP biosynthesis (Moutiez et al. 2014). LC/MS 
analysis following incubation of NozA and NcdA with tryptophanyl-tRNA in vitro, 
revealed production of cyclo(L-Trp-L-Trp).  Eliminating any one component of the 
assay mixture (e.g. enzyme (NozA or NcdA), tryptophan, tRNA or aminoacyl-
tRNA synthetase mix) resulted in no production of cyclo(L-Trp-L-Trp) (Figure 13 
a). These results confirmed that NozA and NcdA, like other characterized 
CDPSs, use aminoacyl-tRNA’s as their substrates to catalyze the production of 
cyclo(L-Trp-L-Trp).  Both NozA and NcdA are most closely related to CDPSs that 
incorporate aromatic aminoacyl-tRNAs (Figure 6). In order to elucidate the 
substrate specificity of NozA and NcdA, both enzymes were incubated with 
tRNAs charged with alternative aromatic amino acids, L-tyrosine and L-
phenylalanine.  LC/MS analysis revealed that NozA and NcdA were not able to 
catalyze the biosynthesis of alternative 2,5-DKPs using these aromatic 
aminoacyl-tRNA substrates, revealing the substrate specificity of both enzymes 
for L-tryptophan charged tRNA (Figure 13 a). 
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a)  b)  
c)  d)  
Figure 12.  SDS-PAGE analysis of NozA and NcdA purification via Ni-column and FPLC. 
(a) NozA Ni-column eluents. Lane 1 contains PageRuler Unstained Protein Ladder 
(Thermo Scientific), lane 2 contains total proteins, lane 3 contains total soluble proteins, 
lane 4 contains the flow through fraction (containing 5 mM imidazole), lane 5 contains 10 
mM imidazole eluent, lane 6 contains 50 mM imidazole eluent, lane 7 contains 200 mM 
imidazole eluent and lane 8 contains 500 mM imidazole eluent. NozA (~28 kDa) was 
eluted in the 200 mM imidazole fraction. (b) NcdA Ni-column eluents.  Lane 1 contains 
PageRuler Prestained Protein Ladder (Thermo Scientific), lane 2 contains the flow 
through fraction (containing 5 mM imidazole), lane 3 contains 10 mM imidazole eluent, 
lane 4 contains 50 mM imidazole eluent, lanes 5-6 contain sequential 100 mM imidazole 
eluent, lanes 7-8 contain sequential 200 mM imidazole eluent and lane 9 contains 500 
mM imidazole eluent. NcdA (~29 kDa) was eluted in both 200 mM imidazole fractions. 
(c-d) FPLC fractions containing >90% pure NozA and NcdA. (c) Lane 1 contains 
PageRuler Prestained Protein Ladder (Thermo Scientific) and lanes 2-5 contain purified 
NozA (~28 kDa).  (d) Lane 1 contains PageRuler Unstained Protein Ladder (Thermo 
Scientific) and lanes 2-5 contain purified NcdA (~29 kDa). These >90% pure fractions 
were pooled for in vitro analyses of enzyme functions.  
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a)	   	  	  
b) 	  	  
Figure 13.  In vitro characterization of NozA and NcdA encoded by the Nocardiopsis sp. 
CMB-M0232 genome. (a) LC/MS revealed that incubation of purified recombinant NozA 
and NcdA with tryptophanyl-tRNA substrates yielded cyclo(L-Trp-L-Trp) in vitro. 
Incubation with alternative aromatic amino acids yielded no alternative 2,5-DKPs (data 
not shown), revealing substrate specificity of both enzymes for tryptophan-charged 
tRNA. Plot shows LC/MS selected ion recording for cyclo(L-Trp-L-Trp) and for cyclo-3-
methyl-L-Trp-N1’-methyl-L-Trp DKP internal standard (I.S.).  (b) These data support the 
overall reaction catalyzed by both NozA and NcdA is to employ tryptophanyl-tRNA 
substrates to yield cyclo(L-Trp-L-Trp) product.  
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These experiments confirmed that NozA and NcdA from Nocardiopsis sp. 
CMB-M0232 catalyze the production of cyclo(L-Trp-L-Trp) both in vivo and in 
vitro. These results suggest both enzymes are involved in the biosynthesis of 
nocardioazine A by producing the 2,5-DKP precursor in the biosynthetic pathway, 
cyclo(L-Trp-L-Trp). These findings make NozA and NcdA two of only three 
characterized CDPSs from prokaryotic origin to use tryptophanyl-tRNA as a 
substrate and two of only three characterized CDPSs from any origin to exhibit 
specificity for a single substrate. Fidelity is uncommon amongst characterized 
CDPSs, making NozA and NcdA important CDPS family additions. 
Characteristic to CDPS-containing biosynthetic pathways are DKP-
tailoring enzymes capable of modifying the CDPS-assembled substrates to 
produce alternative natural products (Gondry et al. 2009, Sauguet et al. 2011, 
Seguin et al 2011, Belin et al. 2012, Giessen and Marahiel, 2012, Giessen et al. 
2013). Chapter three aims to identify putative cyclo(L-Trp-L-Trp) modifying 
enzymes in the noz gene cluster to determine their roles in the modification of 
cyclo(L-Trp-L-Trp) to produce nocardioazines A-B. 
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Chapter III 
Evaluation of tailoring enzymes with hypothesized roles in                           
nocardioazine A biosynthesis 
Introduction 
In prokaryotic organisms, genes involved in secondary metabolic 
pathways are typically organized in operon-like structures within the genome, 
spanning up to 100 kilobases or more (Lane and Moore, 2012). This organization 
in prokaryotes greatly facilitates location of entire biosynthetic pathways 
compared to eukaryotic organisms, where genes involved in a biosynthetic 
pathway are often dispersed among the entire genome. Once a prokaryotic 
biosynthetic gene cluster is located, modern molecular techniques allow probing 
of individual players in the pathway to elucidate their enzymatic functions and 
engineer synthesis of alternative metabolites.  
In the case of peptide derived natural products, two biological strategies 
exist for generating structural diversity: (1) changing the peptide backbone itself 
or (2) modifying the scaffold with various tailoring enzymes (Giessen and 
Marahiel, 2012). The majority of functionally characterized CDPSs exhibit 
promiscuity in their aa-tRNA substrate specificity and are able to incorporate 
multiple amino acids to generate several different 2,5-DKP backbones. NozA and 
NcdA are two of only three CDPSs that exhibit substrate specificity, solely 
catalyzing the production of cyclo(L-Trp-L-Trp) assembly. We focused on gaining 
insight into the function of cytochrome P450 enzymes encoded within the same 
operon as nozA. These enzymes were hypothesized to play roles in the late 
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stages of biosynthesis of the nocardioazines (Figure 14), which share the 
cyclo(Trp-Trp) backbone provided by the Nocardiopsis sp. CDPSs (Chapter 2).  
 
 
Figure 14. Nocardioazine biosynthesis overview. (a) Schematic of proposed 
intermediates in nocardioazine assembly, as established by comparison of synthetic 
standards to metabolites from Nocardiopsis sp. (Alqahtani et al. 2015). In this thesis, 
gene elimination mutations and feeding studies were employed in an effort to evaluate 
the functions of NozD and NozE in the late stages of nocardioazine assembly. (b) 
Overview of genes with predicted roles in nocardioazine assembly.   
 
All CDPS-encoding biosynthetic pathways contain at least a single gene 
encoding a DKP-modifying enzyme positioned upstream or downstream from the 
CDPS gene, indicating that the DKPs generated are ultimately modified further to 
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yield diverse chemical structures (Belin et al. 2012, Giessen and Marahiel, 2014). 
This organization generates a mechanism for biosynthesis of standard cyclic 
peptide scaffolds that can be modified by a variety of enzymes, incorporating 
functional groups that result in unique biologically activities. Exploiting this 
molecular method provides endless opportunities to synthesize new natural 
products and therefore, new candidates for pharmaceutical drugs. 
There are several enzymes characteristic to CDPS-containing pathways 
that can be organized into three groups: modifying enzymes, regulators and 
transporters (Giessen and Marahiel, 2014). Common classes of modifying 
enzymes are hydrolases, methyltransferases, and acyl-CoA transferases. Among 
all, the most common class of tailoring enzymes are the oxidases, with a 
relatively high majority homologous to cytochrome P450s, enzymes that catalyze 
a wide variety of oxidation reactions, including oxygenation reactions on a variety 
of substrates by adding hydroxy and epoxide groups (Giessen and Marahiel, 
2014). Common regulatory enzymes associated with CDPS-containing gene 
clusters are transcription factors. Transcription factors trigger the expression of 
genes in the biosynthetic pathways in response to environmental cues such as 
oxidative stress, toxins and antibiotics. Membrane transporters are also common 
among CDPS-containing gene clusters, generally responsible for exporting the 
products of biosynthesis from the cell. Based on these three enzyme groups, it is 
suggested that environmental cues trigger synthesis of CDPs, which are then 
transported to the periplasm or extracellularly (Belin et al. 2012 & Giessen and 
Marahiel, 2014). 
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NozD and NozE, two cytochrome P450 homologs located directly 
downstream from nozA (Figure 14 & 16; Table 1), were predicted via 
bioinformatics analyses to modify the unique C3’-prenyl group of nocardioazine B 
to form the epoxide ring characteristic to nocardioazine A and is critical to its 
anticancer activity. In this chapter we aim to elucidate the roles of NozD and 
NozE in nocardioazine A biosynthesis by expressing the genes in heterologous 
Streptomyces hosts optimized for the expression of biosynthetic pathways from 
actinomycetes. Constructs engineered to express the gene cluster containing 
nozA, nozD and nozE (Gust et al. 2004, Smanski et al. 2012) as well as three 
additional constructs featuring gene elimination mutations in the gene cluster 
were engineered for expression in Streptomyces.  To probe the functions of the 
three genes from contig 557 (nozA, nozD and nozE) the heterologous 
Streptomyces were exposed to nocardioazine B via in vivo and in vitro methods 
and metabolite profiles were screened via HPLC to detect accumulation of 
nocardiazine A. 
 
Methods 
Isolation of nocardioazines A-B from wild type Nocardiopsis sp. CMB-
M0232 
M1 liquid media (20 mL) (10 g/L potato starch, 4 g/L yeast, 2 g/L peptone, 
1 g/L CaCO3, 40 mg/L Fe2(SO4)5H2O, 100 mg/L KBr, pH 7) was inoculated with 
wild type Nocardiopsis sp. CMB-M0232 from a -80 °C freezer stock and 
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incubated for 6 days and 200 rpm at 30 °C.  Following incubation, 5 x 1 L of M1 
liquid media in Fernbach flasks were inoculated with 1 mL each of the 6-day 
starter culture and incubated at 30 °C and 200 rpm for seven days.  Following 
incubation, the 5 L culture was filtered over Celite 545 (Fisher) and extracted with 
an equal volume of ethyl acetate. The ethyl acetate was removed from the 
aqueous extracts using a vacuum controlled rotavapor (BUCHI) and the 
remaining traces of liquid were dried using a SpeedVac concentrator (Savant 
ISS1100, Thermo Scientific) overnight. 
 Nocardiopsis sp. crude extracts (~600 mg from 5 L culture) were 
subjected to sequential trituration with water, n-hexane, dichloromethane 
(CH2Cl2), and methanol (MeOH) to begin to separate the nocardioazines from 
other compounds.  Specifically, the crude extracts were solubilized in 5 mL of 
Milli-Q water and centrifuged (5,000 rpm for 10 minutes).  The supernatant, 
consisting of water with soluble polar compounds, was discarded.  The remaining 
pellet composed of insoluble, nonpolar compounds was dried using a SpeedVac 
concentrator (Savant ISS1100) and resolublized in n-hexane (50 mL).  The 
suspension was centrifuged and the supernatant was transferred to a scintillation 
vial, dried using a vacuum controlled rotavapor (BUCHI), and set aside for 
LC/MS analysis. The remaining pellet from the hexane suspension was then 
resolublized in CH2Cl2 (50 mL) and handled identically to the hexane suspension. 
This was again repeated using MeOH (50 mL). Dried n-hexane, CH2Cl2 and 
MeOH extracts were resolubilized in MeOH to a final concentration of 10 mg/mL 
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and subjected to LC/MS analysis to determine which fraction contained the 
majority of nocardioazine A-B.  
 LC/MS determined that the n-hexane fraction contained the highest 
concentrations of nocardioazines A-B.  An aliquot (500 µL) of the n-hexane 
extract (10 mg/mL) was subjected to HPLC using an Aligent 1100 HPLC system 
with a ZORBAX SB-C18 column (9.4 x 250 mm, particle size: 5 µm, pore size of 
110 Å). A flow rate of 3.5 mL/min was used, with solvent A consisting of MilliQ 
water, solvent C consisting of acetonitrile and a linear gradient of 10 to 100% 
solvent C over 25 minutes following an 5 minute hold at 10% solvent C. Fractions 
were collected coming off the column in two-minute increments, concentrated 
and analyzed by LC/MS to identify which peaks in the spectra (280 nm) 
correspond to nocardioazine A-B. The respective peaks were collected from the 
remainder of the hexane extracts, dried using a SpeedVac concentrator (Savant 
ISS1100) and solubilized in 100% chloroform-d (Alfa Aesar) to verify their 
chemical structures by nuclear magnetic resonance (NMR).  
 
Generation of heterologous constructs for expression of contig 557 in 
Streptomyces coelicolor M1152 and Streptomyces lividans TK24 
 The SuperCos 1 cosmid clone carrying contig 557, featuring the noz gene 
cluster (Figure 14 & 16, Table 1), was modified for introduction and expression in 
Streptomyces hosts following protocols described by Smanski et al. (2012). 
Specifically, SuperCos-1 (Agilent) carrying contig 557 from a cosmid clone library 
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generated as described by Bis et al. (2015) was modified by λ-RED E. coli 
recombination to introduce oriT, an origin of conjugal transfer, Streptomyces 
θC31 integrase to facilitate integration into the attB site of Streptomyces’ 
chromosome, and aac(3)IV, an apramycin resistance gene for selection.   
A 270 bp fragment of the 3’ end of the bla gene from SuperCos 1 was 
amplified using methods and primers described by Smanski et al. and cloned into 
the XbaI/BamHI sites in the Streptomyces-integrating vector, pSET152 (Bierman 
et al. 1992) which encodes aac(3)IV, oriT and θC31 integrase. The 
pSET152/3’bla construct was then linearized at BamHI and EcoRI restriction 
sites and introduced into λ-RED recombination proficient E. coli BW25113/pIJ790 
carrying SuperCos/contig 557 to undergo homologous recombination between 
the homologous pUC and 3’ -bla sites of the SuperCos backbone. PCR and DNA 
sequencing were used to confirm the presence of aac(3)IV, oriT and θC31 
integrase in SuperCos/contig 557A, the product of this recombination event 
(Appendix C, SuperpSET_F/R).  E. coli ET12567/pUZ8002 was transformed with 
SuperCos/contig 557A to facilitate conjugation into Streptomyces coelicolor 
M1152 and Streptomyces lividans TK24 using standard methods described by 
Gust et al. (2004). PCR confirmed successful integration of contig 557 genes into 
the S. coelicolor M1152 and S. lividans TK24 chromosome (Appendix C, 
NozACtg557_F/R).  
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In vivo and in vitro characterization of NozD and NozE heterologously 
expressed in Streptomyces 
NozD and NozE, cytochrome P450 homologs (Table 1) were predicted via 
bioinformatics analyses as the most likely candidates for the modifications made 
to nocardioazine B to produce nocardioazine A, which requires cyclizing of the 
C3’-prenyl group on nocardioazine B to form the epoxide ring on nocardioazine A 
(Figure 14). To determine the role of NozD and NozE in this catalytic reaction, in 
vivo and in vitro experiments were designed using heterologous Streptomyces 
carrying the entire contig 557 including NozA, NozD and NozE.  
For the in vivo approach, S. coelicolor M1152 and S. lividans TK24 
heterologously expressing the contig 557 gene cluster (including NozA, NozD 
and NozE) were cultured in media supplemented with nocardioazine B, extracted 
and analyzed for the presence of nocardioazine A. Specifically, 100 µL of 3-day 
starter cultures of heterologous S. coelicolor M1152 and S. lividans TK24 carry 
contig 557 were inoculated into 25 mL of M1 media supplemented with 50 µg/mL 
apramycin in 250 mL Erlenmeyer flasks. Wild type S. coelicolor M1152 and S. 
lividans TK24 carrying no biosynthetic genes were cultured alongside as 
controls, lacking apramycin. Two 25 mL cultures of each treatment and control 
strain were prepared and supplemented as follows prior to fermentation. One 
culture of each wild type strain and heterologous strain was supplemented with 
250 µg nocardioazine B that was solubilized in dimethyl sulfoxide (DMSO). The 
second set of cultures was supplemented with equal volumes of DMSO to serve 
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as controls. The treatment and control cultures were incubated at 30 °C and 200 
rpm for 6 days.  
Following incubation, the cultures were extracted with 25 mL of EtOAc and 
the chemical extracts were concentrated using a vacuum controlled rotavapor 
(BUCHI) followed by a SpeedVac concentrator (Savant ISS1100, Thermo 
Scientific) overnight. The extracts were resolubilized in 250 uL MeOH for analysis 
by HPLC to determine whether NozD and NozE were able to convert 
nocardioazine B to nocardioazine A. The HPLC method mentioned previously 
was run with known concentrations of cyclo(L-Trp-L-Trp) (0.2 mg/mL), 
nocardioazine B (25 µM) and nocardioazine A (25 µM) to serve as positive 
controls. 
The in vitro approach offered an alternative that exposed nocardioazine B 
to cell lysates containing NozD and NozE rather than requiring nocardioazine B 
enter the cell as in the in vivo methods. Specifically, 200 µL of 3-day starter 
cultures of heterologous S. lividans TK24 carrying contig 557 (NozA, NozD and 
NozE) were inoculated into 50 mL of M1 media supplemented with 50 µg/mL 
apramycin in 250 mL Erlenmeyer flasks. Wild type S. lividans TK24 was cultured 
alongside as a control, lacking apramycin.  Following 3 days and 6 days of 
incubation at 30 °C and 200 rpm, 25 mL of each culture (wild type control and 
treatment carrying contig 557) were transferred to 50 mL falcon tubes. The cells 
were harvested by centrifugation (6,000 rpm, 4°C) and were resuspended in 3 
mL lysis buffer (100 mM Tris HCl, 150 mM NaCl, 5% glycerol, 2 mM DTT, pH 8) 
with lysozyme (3.75 mg).  The cell suspensions were sonicated at 60% amplitude 
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for 3 minutes (1 s pulse:10 s rest). Cell debris was removed by centrifugation 
(12,000 rpm, 4 °C) and the soluble lysates were filtered through a 0.45 µM 
cellulose acetate membrane (Corning). In 1.5 mL microtubes, 100 µL of cell 
lysates were combined with 20 µL of DMSO-solubilized nocardioazine (100 µg). 
To serve as controls, duplicate assays were set up that combined 100 µL of cell 
lysates with 20 µL of DMSO (no addition of nocardioazine B). The assays were 
incubated ~16 hours at 30 °C.  Following incubation, the assays were extracted 
with 1 mL EtOAc and the chemical extracts were dried using a vacuum controlled 
rotavapor (BUCHI) followed by a SpeedVac concentrator (Savant ISS1100, 
Thermo Scientific) overnight. The extracts were resolubilized in 100 uL MeOH for 
analysis by HPLC, described previously, to determine whether NozD and NozE 
converted nocardioazine B to nocardioazine A.  
 
Generation of PCR-targeted gene replacements in the contig 557 gene 
cluster for heterologous expression in Streptomyces coelicolor M1152 and 
Streptomyces lividans TK24 
 Additional constructs were created with PCR-targeted gene deletions to 
further probe the enzymatic functions of NozA and the two cytochrome P450s 
encoded downstream from nozA, referred to a NozD and NozE. Three constructs 
were designed, each with one of the three abovementioned genes deleted in a 
manner that would not interfere with expression of the other genes following 
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procedures described by Smanski et al. (2012) and Gust et al. (2004) (Figure 
15).  
Specifically, gene disruption was carried out via PCR to replace each 
targeted biosynthetic gene with an apramycin resistance cassette flanked with 
FLP recognition targets (FRTs) (Figure 15 a). The FRTs were engineered into 
the cassettes for FLP recombinase-induced excision of the apramycin resistance 
gene to yield an in-frame scar in place of the gene. First, PCR was conducted to 
amplify the FLP-flanked apramycin resistance gene by using primers with regions 
homologous to the region immediately up- and downstream from the biosynthetic 
gene targeted for replacement (Figure 15 a). The PCRs contained 36 µL of 
molecular biology grade water, 0.5 µL of each forward and reverse primer 
(NozX::scarKO_F/R, Appendix C) (0.5 µM final concentration), 5 µL of 10X 
Expand High Fidelity Buffer with MgCl2 (Roche), 0.5 µL of High Fidelity dNTPs 
(10 mM final concentration of each dNTP), 2.5 µL of DMSO, 0.5 µL (~50 ng) of 
template DNA (AprR cassette from pIJ773 vector) and 1 µL of Expand High 
Fidelity Enzyme Mix (Roche). The PCR reactions ran for an initial denaturation of 
94 °C for 2 min, 10 cycles of 94 °C for 45 s, 50 °C for 45 s, 72 °C for 90 s, 15 
cycles of 94 °C for 45 s, 55 °C for 45 s, 72 °C for 90 s and a final extension of 72 
°C for 5 min. The PCR products were verified for size by agarose gel 
electrophoresis and the remaining PCR product was purified using a QIAquick 
PCR Purification Kit.   
Following amplification of the apramycin resistance cassette, 
SuperCos/contig 557 was introduced into E. coli BW25113/pIJ790 via 
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electroporation (Figure 15 b). Next, the PCR-amplified apramycin resistance 
cassette was introduced into E. coli BW25113/pIJ790/SuperCos/contig 557 
(Figure 15 b). In three separate constructs, one of each of the desired genes 
(nozA, nozD or nozE) was replaced with the FRT-flanked apramycin resistance 
cassette, aac(3)IV, via λ-RED recombination to generate SuperCos/nozA::AprR, 
SuperCos/nozD::AprR and SuperCos/nozE::AprR constructs (Figure 15 c). PCR 
confirmed recombination between the SuperCos/contig 557 cosmids and the 
AprR cassette.  
Prior to conjugation with Streptomyces, the SuperCos/contig 557 
constructs carrying apramycin disruption cassettes in place of nozA, nozD, or 
nozE required further modification. This modification required exploiting FLP 
recombinase to replace the disruption cassette with an 81 bp scar to create non-
polar, in-frame deletions (nozA::scar, nozD::scar, nozE::scar). SuperCos carrying 
the apramycin disruption cassettes were introduced into E. coli DH5α/BT340 (E. 
coli Genetic Stock Center: Strain# 7629) via standard electroporation (Figure 15 
d). Incubation at 42 °C induced expression of the FLP-recombination plasmid, 
BT340, to express FLP-recombinase, which recognizes the FRT regions, 
resulting in excision of the apramycin resistance cassette. This leaves behind an 
81 bp “scar” in the correct reading frame (Figure 15 e).  PCR confirmed the 
presence of the 81 bp “scars” in each construct (Appendix C, 
NozX_KOCon_F/R). 
Following protocols mentioned in the previous section, these three 
SuperCos cosmids now carrying the contig 557 with an 81 bp “scar” in place of 
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NozA, NozD or NozE were again introduced into λ-RED recombination proficient 
E. coli BW25113/pIJ790 carrying the previously constructed pSET152/3’bla 
linearized plasmid DNA (Smanski et al. 2012). Homologous recombination 
between the pUC origin of replication and 3’ -bla sites introduced oriT, 
Streptomyces θC31 integrase, and aac(3)IV into SuperCos to facilitate 
conjugation (Figure 15 f). PCR and DNA sequencing were used to confirm the 
presence of aac(3)IV, oriT and θC31 integrase in the products of the 
recombination event (Appendix C, SuperpSET_F/R).  
Each of the SuperCos/noz::scar constructs (nozA::scar, nozD::scar, 
nozE::scar) were introduced into E. coli ET12567/pUZ8002 to facilitate 
conjugation into S. coelicolor M1152 and S. lividans TK24 using standard 
methods described by Gust et al. (2004) (Figure 16 g-h). PCR amplification 
confirmed successful integration of the nozA::scar, nozD::scar and nozE::scar 
constructs into Streptomyces chromosome (Appendix C, NozX_KOCon_F/R).  
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Figure 15. Methods for generating PCR-targeted gene deletions in the noz gene cluster 
and introducing the constructs into heterologous Streptomyces via conjugation. (a) An 
apramycin resistance cassette from pIJ773 was PCR amplified using primers that 
introduced homologous regions of the gene to be deleted both upstream and 
downstream from the apramycin resistance cassette. (b) SuperCos1-contig 557 from the 
cosmid clone library and the PCR amplified apramycin resistance cassette were both 
introduced into E. coli BW25113/pIJ790 to undergo homologous recombination. (c) 
Homologous recombination replaced the targeted gene in contig 557 with the apramycin 
resistance cassette. (d) SuperCos/contig 557/noz::AprR was introduced into E. coli 
DH5α/BT340. (e) FLP-recombinase was expressed by the BT340 plasmid, which 
recognized FRT sequences flanking the apramycin resistance cassette and excised the 
cassette, leaving behind an 81-bp, in frame ‘scar’. (f) SuperCos/contig 557/noz::scar was 
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introduced into E. coli BW25113/pIJ790 and underwent homologous recombination with 
pSET152/bla to introduce elements into the plasmid DNA necessary for conjugation with 
Streptomyces chromosome. (g) SuperCos/contig 557/noz::scar underwent conjugation 
with Streptomyces to integrate the SuperCos plasmid into Streptomyces via homologous 
recombination. (h) SuperCos/contig 557/noz::scar was introduced into Streptomyces 
chromosome.  
 
Comparison of metabolite profiles between heterologous S. coelicolor 
M1152 and S. lividans TK24 carrying contig 557 or contig 557/nozA::scar, 
nozD::scar or nozE::scar  
 Metabolite profiles were compared between Streptomyces featuring 
heterologous noz cluster expression constructs (contig 557, nozA::scar, 
nozD::scar and nozE::scar) to screen for the production of alternative metabolites 
as a result of the PCR-targeted gene replacements. Specifically, one hundred 
microliters of 3-day starter cultures of heterologous S. coelicolor M1152 and S. 
lividans TK24 constructs (contig 557, nozA::scar, nozD::scar, nozE::scar) were 
inoculated into 10 mL of M1 media (lacking Instant Ocean) supplemented with 50 
µg/mL apramycin in 50 mL falcon tubes.  Wild type S. coelicolor M1152 and S. 
lividans TK24 were cultured alongside as controls lacking the addition of 
apramycin. The treatment and control cultures were run in duplicates and 
incubated at 30 °C and 200 rpm for 5 days. Following incubation, the cultures 
were extracted with 10 mL EtOAc. The chemical extracts were dried using a 
vacuum controlled rotavapor (BUCHI) and the remaining extracts were dried 
using a SpeedVac concentrator (Savant ISS1100, Thermo Scientific) overnight. 
The extracts were resolubilized in 150 µL MeOH for analysis by HPLC, described 
	   58	  
previously. Chemical profiles produced were compared using ChemStation 
(Agilent). 
 
Results and Discussion 
Bioinformatics analyses predicted biosynthetic pathways from 
Nocardiopsis sp. 
FGENESB (Softberry) was used to predict putative genes and their 
corresponding protein sequences upstream and downstream from nozA and 
ncdA, CDPSs responsible for catalyzing cyclo(L-Trp-L-Trp) assembly. The CDPS 
enzymes were found to reside in two different regions of Nocardiopsis sp. 
genome, resulting in two CDPS-containing biosynthetic gene clusters, referred to 
as contig 557 and contig 96 (Table 1, Figure 16 a-b). The contig 557 gene cluster 
spans approximately 15 Kb and contains a CDPS homolog (nozA) along with 
several other putative DKP tailoring enzymes. Two tailoring enzymes of interest 
within the contig 557 gene cluster were identified as cytochrome P450 homologs 
and named NozD and NozE. The genes encoding NozD and NozE are located 
directly downstream from nozA and play hypothesized roles in the cyclization of 
the C3’-normal prenyl group of nocardioazine B to yield the group observed in 
nocardioazine A (Table 1, Figure 16 a). Additional bioinformatics analyses of 
Nocardiopsis sp. CMB-M0232 genome revealed another gene cluster, contig 
119, with hypothesized roles in nocardioazine biosynthesis (Table 1, Figure 16 
c). A putative prenyltransferase, NozC, is hypothesized to catalyze the C3’-
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normal prenylation of the DKP core first seen in nocardioazine B.  In this same 
gene cluster and directly upstream from NozC is NozB, a putative 
methyltransferase with hypothesized roles in C- and N-methylations of the DKP 
scaffold also first seen in nocardioazine B (Figure 14).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   60	  
Table 1.  Predicted functions and homologs of putative proteins encoded by the 
hypothesized nocardioazine biosynthetic gene clusters: contig 557, contig 96 and contig 
119. # aa = number of amino acid residues; ID = % identity; Sim = % Similarity. 
 
contig 557 
genes (bp) # aa BLASTP annotation
NCBI accession 
number of homolog
ID / Sim 
(%)
1512-2777 421 pyridoxas-5'-phosphate-dependent 
protein subunit beta
WP_037674793 56/69
2842-4050 402 major facilitator superfamily 
transporter
AEF16056 58/72
4093-4155 20 beta-N-acetylglucosaminidase KFA31228 73/90
4235-4939 234 tRNA-dependent cyclodipeptide 
synthase
WP_033352817 42/53
5023-6219 398 cytochrome P450 WP_045298286 40/54
6312-7373 353 cytochrome P450 WP_045298286 40/54
7451-9994 847 adenylocsuccinate synthetase ELQ79671 58/69
10221-10550 109 4-carboxymuconolactone 
decarboxylase
WP_020270970 75/87
10810-11733 307 XRE family transcriptional regulator WP_044572329 80/89
11721-12809 362 ABC transporter ATP-binding 
protein
WP_046471802 73/82
12806-13675 289 molybdate ABC transporter WP_017566834 76/88
13947-14780 277 molybdate-binding protein WP_046471807 71/78
14773-15183 136 MerR family transcriptional 
regulator
WP_017544945 76/84
15254-15904 216 hypothetical protein ERT00338 36/52
contig 96 
genes (bp) # aa BLASTP annotation
NCBI accession 
number of homolog
ID / Sim 
(%)
1-379 126 cell division protein WP_033301593 72/83
431-1063 210 hypothetical protein WP_033301600 36/49
1527-3068 513 AMP-dependent synthetase WP_042418882 74/82
3083-3811 242 CDPS WP_035283888 70/80
3897-4760 287 cell wall hydrolase WP_026126175 63/71
4924-5283 119 hypothetical protein WP_017620737 69/84
5502-6452 316 erythromycin esterase WP_046725140 38/51
6846-7481 211 transcriptional regulator WP_011211565 58/74
7689-9269 526 peptide ABC transporter substrate-
binding protein
WP_041588039 40/57
9435-9824 129 extradiol dioxygenase WP_033381084 78/85
9947-10945 332 nickel ABC transporter permease WP_015051569 41/55
10970-11806 278 serine protease WP_037956543 55/72
11949-12185 78 multidrug transporter WP_031172074 57/70
12310-12423 37 polyketide synthase PKS1 AGL28386 52/58
12967-13338 123 beta-galactosidase WP_019609329 57/62
contig 119 
genes (bp) # aa BLASTP annotation
NCBI accession 
number of homolog
ID / Sim 
(%)
105-1118 337 hypothetical protein WP_017620974 73/82
1223-2152 309 3-ketoacyl-ACP reductase WP_026126235 77/84
2501-3805 434 glycosyl transferase family 1 WP_017620972 85/92
3916-4554 212 methyltransferase WP_046468151 86/92
4551-5627 358 prenyltransferase WP_033301783 79/84
5668-8013 781 hypothetical protein WP_040270987 69/81
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Figure 16.  Bioinformatics-predicted Nocardiopsis sp. gene clusters with hypothesized 
roles in cyclo(L-Trp-L-Trp) and nocardioazine A-B biosynthesis. Cluster a) represents 
contig 557 which spans ~15 Kb, b) represents contig 96 which spans ~15 Kb and c) 
represents contig 119, spanning ~8 Kb.  Arrows indicate the predicted direction of gene 
transcription. Chapter 2 established the function of the cyclodipeptide synthases (red) in 
production of cyclo(L-Trp-L-Trp).  
 
 Most CDPS-containing natural product biosynthetic pathways carry genes 
encoding oxidases and almost all contain a gene encoding a cytochrome P450.  
But, contig 557 presents the only identified natural product biosynthetic pathway 
thus far that encodes two cytochrome P450s directly downstream from a CDPS 
gene, suggestive of unique tailoring capabilities from the contig 557 gene cluster.  
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Isolation of nocardioazines A-B from wild type Nocardiopsis sp. CMB-
M0232 
Nocardioazines A-B were isolated from wild type Nocardiopsis sp. CMB-
M0232 in order to ‘feed’ heterologous Streptomyces the putative precursors in 
nocardioazine A biosynthesis and to provide a standard of the pathway end 
product, nocardioazine A. Following EtAOc extraction of wild type Nocardiopsis 
sp. CMB-M0232, the crude extracts were subjected to sequential trituration to 
concentrate the nocardioazines in a single fraction. LC/MS identified the largest 
quantities of nocardioazine A-B present in the n-hexane extracts, a result of their 
relatively non-polar chemical structures. To determine which peaks from the n-
hexane fraction HPLC spectra were representative of nocardioazines A-B, 
eluents were collected from the HPLC column in two-minute increments. LC/MS 
identified that nocardioazine A eluted from the column between minutes 26 and 
28 (Figure 17 a) and nocardioazine B eluted from the column between minutes 
28 and 30 (Figure 17 b). LC/MS then confirmed the individual peaks within those 
time frames that were representative of nocardioazine A-B. From 5 L of 
Nocardiopsis sp. CMB-M0232 culture, ~3.0 mg of nocardioazine B (pale white 
powder) was purified and ~1.5 mg of nocardioazine A (pale white powder) was 
purified. NMR validated the chemical structure of the purified compounds, 
confirming isolation of pure, nocardioazines B and nocardioazine A (Appendix E-
F). 
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Figure 17.  HPLC spectra of n-hexane extracts that contain (a) nocardioazine A and (b) 
nocardioazine B. Peaks (a) and (b) were collected and their contents verified via NMR. 
Chromatogram shows absorbance at 280 nm.          
 
 
Generation of noz cluster constructs for heterologous expression in 
Streptomyces 
 To facilitate conjugation with Streptomyces, the SuperCos cosmid from 
the gDNA clone library carrying contig 557 (called SuperCos/557 and featuring 
the noz cluster of genes including nozA, nozD and nozE) as well as the 
SuperCos cosmids carrying contig 557 featuring PCR-targeted mutants 
(nozA::scar, nozD::scar and nozE:: scar) underwent homologous recombination 
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with a fragment of the pSET152 plasmid vector to introduce the following 
elements into SuperCos: aac(3)IV, oriT and θC31 integrase. These components 
are essential for the introduction and expression of genes carried by SuperCos 
(i.e. noz genes) in Streptomyces hosts. PCR confirmed homologous 
recombination between SuperCos constructs carrying mutated (noz::scars) and 
unmutated contig 557 and the linearized pSET152 plasmid vector using two sets 
of primers that were designed to amplify both ends of the region where this DNA 
was introduced into SuperCos. The constructs confirmed to carry all three 
elements were introduced into S. coelicolor M1152 and S. lividans TK24 (Figure 
18) by conjugation.  
 
 
Figure 18. Agarose gel verifying homologous recombination between SuperCos1 
featuring Streptomyces gene expression elements from pSET152 plasmid vector. Lanes 
2-5 contain the amplified region of the constructs spanning the pUC-AprR gene and were 
expected to amplify a 1301 bp product. Lanes 6-9 contain the amplified region of the 
constructs linking the bla from SuperCos with pSET152 and were expected to amplify a 
700 bp product. Lane 1 contains GeneRuler 1 kb Plus DNA Ladder, lanes 2 and 6 
contain SuperCos carrying contig 557, lanes 3 and 7 contain SuperCos carrying the 
nozA::scar, lanes 4 and 8 contain SuperCos carrying the nozD::scar, and lanes 5 and 9 
contain SuperCos carrying the nozE::scar.  
  
	   65	  
 Following conjugation, candidate Streptomyces transformants were 
screened via PCR to confirm the incorporation of contig 557 or the contig 557 
featuring PCR-targeted mutants (nozA::scar, nozD::scar and nozE::scar) into 
Streptomyces chromosome.  The ~3 Kb region of the contig 557 gene cluster 
carrying nozA, nozD and nozE was confirmed present in both S. coelicolor 
M1152 and S. lividans TK24 transformants using PCR (Figure 19). The mutants 
were also confirmed present in both strains of Streptomyces transformants 
(Figure 20). The unmutated contig 557 gDNA served as a positive control to 
identify successful gene replacement and allow comparison of metabolites 
between treatments and controls. Colony PCRs of cultures featuring contig 557 
revealed amplification of the gene of interest.  Replacement of the gene with an 
81 bp-scar resulted in the expected reduction of the PCR product size. 
 
 
Figure 19. Agarose gel verifying integration of contig 557, containing nozA, nozD and 
nozE, into S. coelicolor M1152 and S. lividans TK24. Lane 1 contains GeneRuler 1kb 
Plus DNA Ladder and lanes 2-4 contain contig 557 integrated into S. coelicolor M1146 
which was not used in this current thesis study due to failed conjugation of mutant contig 
557 constructs with S. coelicolor M1146. Lanes 5-7 contain contig 557 integrated into S. 
coelicolor M1152, lanes 8-9 contain contig 557 integrated into S. lividans TK24, and lane 
10 contains the pSET152/contig 557 cosmid to serve as a PCR control.  PCR amplified 
an ~500 bp region of nozA to confirm the presence of the contig 557 gene cluster in 
Streptomyces.   
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a)    b)  
c)  
Figure 20. Agarose gels verifying integration of contig 557 gene elimination mutations 
via PCR-targeted gene deletions into S. coelicolor M1152 and S. lividans TK24. (a-c) 
Lane 1 contains GeneRuler 1kb Plus DNA Ladder, lanes 2-3 contain S. lividans TK24 
and S. coelicolor M1152 carrying the contig 557/noz::scars, respectively, lanes 4-5 
contain S. lividans TK24 and S. coelicolor M1152 carrying contig 557 (unmutated), 
respectively, and lane 6 contains SuperCos-1 carrying contig 557 to serve as a PCR 
control.  Gel (a) contains Streptomyces carrying the contig557/nozA::scar constructs, gel 
(b) contains Streptomyces carrying the contig557/nozD::scar constructs, and gel (c) 
contains Streptomyces carrying the contig557/nozE::scar constructs. The reduction in 
size observed in the gene deletion constructs indicates deletion of that gene compared 
to the constructs carrying the entire gene cluster.  
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In vivo characterization of functions of NozD and NozE exposed to 
nocardioazine B to evaluate their roles in biosynthesis of nocardioazine A 
Nocardioazine B, purified from wild type Nocardiopsis sp. CMB-M0232, 
was fed to Streptomyces expressing contig 557 genes, including nozA, nozD and 
nozE.  HPLC was used to evaluate accumulation of nocardioazine A from these 
cultures, since NozD and/or NozE were hypothesized to catalyze the 
transformation of nocardioazine B to nocardioazine A. Metabolite profiles were 
compared between control, wild type S. lividans TK24 and S. coelicolor M1152, 
with treatments of these strains carrying the contig 557 gene cluster (including 
nozA, nozD, and nozE) following fermentation supplemented with nocardioazine 
B (Figure 21-22). HPLC spectra were compared to synthetic cyclo(L-Trp-L-Trp) 
and pure nocardioazine A-B standards to determine the presence of these 
metabolites. Cyclo(L-Trp-L-Trp) was present in all metabolite profiles from 
Streptomyces carrying the contig 557 gene cluster, supporting that the gene 
encoding NozA was translated in the correct reading frame and therefore, 
suggesting NozD and NozE from the same operon were  present in the cells as 
well. Nocardioazine B was detected by HPLC in samples in which it was 
supplemented, but nocardioazine A was not detected in the chemical profiles of 
Streptomyces expressing NozD and NozE and provided nocardioazine B (Figure 
21-22).  It is unclear whether or not nocardioazine B was able to enter the cells to 
interact with NozD and NozE, offering one possibility as to why there was no 
detectable accumulation of nocardioazine A. Thus, an in vitro approach was 
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undertaken to circumvent the issue of nocardioazine B entering the cell and 
instead allow for direct contact between nocardioazine B, NozD and NozE.   
 
 
Figure 21.  HPLC spectra comparing metabolite profiles from heterologous 
Streptomyces lividans TK24 carrying contig 557 exposed to nocardioazine B and not 
exposed to nocardioazine B, in vivo.  Synthetic cyclo(L-Trp-L-Trp) and purified 
nocardioazines A-B serve as controls. Following fermentation of S. lividans TK24 
carrying contig 557 in media supplemented with nocardioazine B, nocardioazine A was 
not detected. Chromatograms show absorbance at 254 nm.          
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Figure 22.  HPLC spectra comparing metabolite profiles from heterologous 
Streptomyces coelicolor M152 carrying contig 557 exposed to nocardioazine B and not 
exposed to nocardioazine B, in vivo.  Synthetic cyclo(L-Trp-L-Trp) and purified 
nocardioazines A-B serve as controls. Following fermentation of S. coelicolor M1152 
carrying contig 557 in media supplemented with nocardioazine B, nocardioazine A was 
not detected. Chromatograms show absorbance at 254 nm.          
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Following the in vivo results failing to show NozD- or NozE-catalyzed 
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lysates from control, wild type S. lividans TK24 and treatments of this strain 
carrying the contig 557 genes (nozA, nozD and nozE) with pure nocardioazine B. 
The metabolite profiles from the previous mentioned assays were compared to 
the chemical profiles from control and treatment S. lividans TK24 lysates that 
were incubation without the addition of nocardioazine B (Figure 23). This 
approach did not require that nocardioazine B enters the cell to interact with 
NozD and NozE, but instead provided direct contact between nocardioazine B 
and the cell lysates containing the cytochrome P450s, NozD and NozE.   
HPLC metabolite profiles were compared to the cyclo(L-Trp-L-Trp) and 
nocardioazine A-B standards to detect the presence of these metabolites. As 
expected, cyclo(L-Trp-L-Trp) was present in all metabolite profiles from 
Streptomyces carrying the contig 557 gene cluster. Nocardioazine B was 
detected in the samples in which it was supplemented but Nocardioazine A was 
not detected in the chemical profiles where Streptomyces expressing NozD and 
NozE were provided nocardioazine B in vitro. These data suggested that either 
NozD and/or NozE were not adequately expressed, lacked essential cofactors for 
activity when expressed in Streptomyces hosts, or catalyzed reaction(s) other 
than the modifications of nocardioazine B to A.  Thus, the possibility that these 
enzymes carry out other modifications of cyclo(L-Trp-L-Trp), from NozA, was 
next explored.  
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Figure 23. HPLC spectra comparing metabolite profiles from in vitro treatment assays 
that combined cell lysates from Streptomyces lividans TK24 carrying contig 557 with 
nocardioazine B and control assays where lysates incubated without the addition of 
nocardioazine B (blue). Treatments included cell lysates from 3-day (red) and 6-day 
cultures of Streptomyces treatments incubated with nocardioazine B (green). Following 
incubation of the lysates with nocardioazine B, nocardioazine A was not detected. 
Furthermore, no alternative metabolites were detected in assays incubated with 
nocardioazine B compared to the control that was incubated without the addition of 
nocardioazine B.  Chromatograms show absorbance at 210 nm.  
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possibility that these enzymes directly modify cyclo(L-Trp-L-Trp). Metabolite 
profiles from Streptomyces carrying individual PCR-targeted mutations from the 
contig 557 cluster (nozA::scar, nozD::scar or nozE::scar) were compared to 
Streptomyces carrying the entire contig 557 gene cluster to detect accumulation 
of alternative metabolites accumulated upon deletion of any of the three genes 
(Figure 24-25). Cyclo(L-Trp-L-Trp) was present in each metabolite profile from 
heterologous Streptomyces except the nozA::scar mutant, where nozA was 
deleted. This further linked nozA to the production of cyclo(L-Trp-L-Trp) and 
corroborated the finding from chapter 2. The presence of cyclo(L-Trp-L-Trp) in 
the other constructs suggested that the genes were being translated in the 
correct reading frame and that polar effects did not result from gene deletions.  
No metabolites were present in Streptomyces carrying contig 557 but 
missing from those carrying the nozD::scar and nozE::scar gene mutants by 
HPLC (Figure 24-25).  Thus, the enzymatic functions of the cytochrome P450s, 
NozD and NozE, are still yet to be confirmed. Similarities of the chromosomal 
region surrounding nozA to other CDP-modifying biosynthetic pathways, still 
suggest that contig 557 contains likely candidates for the tailoring of 
nocardioazine B to form nocardioazine A.  Further studies utilizing purified 
recombinant enzymes may allow establishment of the functions of NozD and 
NozE by permitting careful control over enzyme concentrations, cofactors, and 
other variables that strongly impact enzyme activity. This thesis study sets the 
stage for such future studies.  
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Figure 24. HPLC spectra comparing metabolite profiles between heterologous 
Streptomyces lividans TK24 carrying the full 557 gene cluster (nozA, nozD and nozE) 
and those carrying the PCR-targeted gene mutants (nozA::scar, nozD::scar and 
nozE::scar). Synthetic cyclo(L-Trp-L-Trp) served as a control.  Depletion of cyclo(L-Trp-
L-Trp) production in the nozA::scar mutant further confirmed the function of nozA in 
cyclo(L-Trp-L-Trp) assembly. No metabolites differed between metabolite profiles from 
S. lividans TK24 carrying contig 557 and those carrying contig 557 with PCR-targeted 
gene deletions. Chromatograms show absorbance at 210 nm.  
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Figure 25. HPLC spectra comparing metabolite profiles between heterologous 
Streptomyces coelicolor M1152 carrying the full 557 gene cluster (nozA, nozD and 
nozE) and those carrying the PCR-targeted gene mutants (nozA::scar, nozD::scar and 
nozE::scar). Synthetic cyclo(L-Trp-L-Trp) served as a control.  Depletion of cyclo(L-Trp-
L-Trp) production in the nozA::scar mutant further confirmed the function of nozA in 
cyclo(L-Trp-L-Trp) assembly. No metabolites differed between metabolite profiles from 
S. coelicolor M1152 carrying contig 557 and those carrying contig 557 with PCR-
targeted gene deletions. Chromatograms show absorbance at 210 nm.  
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Conclusions and Future Directions 
 This thesis study provides insight into the biosynthetic pathway from 
Nocardiopsis sp. CMB-M0232 responsible for the catalytic assembly of the 
nocardioazines, novel 2,5-DKP natural products particularly interesting due to 
their unique chemical structures and the promise of nocardioazine A as an 
anticancer agent. Two CDPS homologs identified in the draft genome sequence 
of Nocardiopsis were biochemically characterized via in vivo and in vitro methods 
to reveal that each catalyzes the production of cyclo(L-Trp-L-Trp), the 
hypothesized precursor in the nocardioazine biosynthetic pathway. Evaluation of 
the substrate specificity of NozA and NcdA revealed that both CDPSs are 
specific for tryptophanyl-tRNA substrates, catalyzing the production of cyclo(L-
Trp-L-Trp) and no other 2,5-DKPs with alternative aromatic aminoacyl-tRNAs. 
This finding renders NozA and NcdA two of only three characterized CDPSs that 
are substrate specific, incorporating only one aminoacyl-tRNA substrate. 
Furthermore, Nocardiopsis provides a rare example of a single bacterium 
encoding two distinct enzymes that catalyze biosynthesis of the same secondary 
metabolite. The physiological relevance of DKP-derived natural products is still 
largely speculative, as little is known about the actual use of these metabolites in 
the native organism. A more thorough understanding of their biological 
importance may provide clues as to why Nocardiopsis has evolved to use two 
phylogenetically identical enzymes in the biosynthesis of cyclo(L-Trp-L-Trp), a 
precursor of the nocardioazines.   
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 The chromosomal region surrounding nozA contains putative CDP-
tailoring enzymes with roles predicted in the modifications made to nocardioazine 
B to produce nocardioazine A. NozD and NozE, two cytochrome P450 homologs 
downstream from nozA were heterologously expressed with NozA in 
Streptomyces to determine their involvement in assembly of nocardioazine A. 
The approaches employed by this study were not able to confirm the enzymatic 
activity of these enzymes, but lead the way toward future studies to optimize the 
conditions for probing NozD and NozE activity.  In addition, future work will aim to 
elucidate the biological properties of the methyltransferase and prenyltransferase 
homologs, NozB and NozC, respectively, from contig 119. These enzymes are 
also hypothesized to play roles in nocardioazine assembly (Figure 14). 
Uncovering their roles in the biosynthesis may link cyclo(L-Trp-L-Trp) produced 
by NozA and NcdA with the modified scaffold characteristic of nocardioazine B.   
 The results gathered from this thesis study have offered novel 
cyclodipeptide-synthesizing enzymes, adding to the knowledge of a relatively 
understudied class of enzymes that offer novel natural products. The 
characterization of NozA and NcdA combined with future work to better 
understand the unique engineering of the C3’-prenyl functional group and other 
nocardioazine groups by Nocardiopsis may provide new opportunities for 
pathway engineering to produce new bioactive drugs. 
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Appendix 
Appendix A.  Sequence of the E. coli optimized nozA gene, optimized and synthesized 
by GeneArt (Life Technologies).  
 
 
 
 
 
 
 
 
 
 
 
 
 
nozA
GAATTGGCGGAAGGCCGTCAAGGCCACGTGTCTTGTCCAGAGCTCCATATGCA
TACCGTTAGCGTTGAACGTGATGGTGATTTTCATGTTACACCGCTGACCGATAAT
TGTCGTGATCTGATGAAAGCCGGTGGTCATGCACTGCTGGGTGTTAGCCATGG
TAATAGTTATTTTAGCCGTGGTCGTCTGAGCAACCTGTTTGCATGGGCACTGCG
TCGTTTTGATGCAGTTGATGTTGTTGCAGCAGATAGCCATGTTGTGGAAATTTTT
CGTGCCATTGGCTATGATGATGAACATGCACGTAAACGCACCCATAAAGAAACC
AGCGTTCTGCGTAATCGTATTCGTGATGCAGCAGCACAGTGTGGTGCAGATCG
TACCCGTATTACCCTGCGTGGTCTGAGCGATTTTATGGATGATCCGGCATATCGT
AGCGTTCTGAGCGAAACCCAGAAAGCACTGGATGATCAGCCGGAATTTCGTAA
TGCAGCCCGTGCAATGACCCGTGCAGTTCTGGAAAGCCGTCTGGGTCCGGGT
AATGCACGTGAAGATCAGATTGATATTGCCTTTAGCTATCTGCAGGCAGAACTG
CCGTTTTTTCATGATGCACCGCGTATTCTGCGTGTTGAAAGCACCGTTAGCTGT
TATCACATGCGTCTGCCGCTGCTGGATTTTATCTGTGGTCCGCGTGCAGTTGTT
CCGGTTGTGCCGACCCAGGGTTTTGCCGTTGTTCGTCCGGCAGATCCGGGTA
AGCTTGGTACCTGGAGCACAAGACTGGCCTCATGGGCCTTCCGCTCACTG
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Appendix B.  Sequence of the E. coli optimized ncdA gene, optimized and synthesized 
by GeneArt (Life Technologies).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ncdA
ATTGGCGGAAGGCCGTCAAGGCCACGTGTCTTGTCCAGAGCTCCATATGAGC
GGTCCGCATGCAGTTCCGGATGGTGGTAGCGCACCGCCTCCGAGCCGTCGTG
CCAGCTTTACCGTTGAACCGTTTACCGATGCATGTCATGCAGTTTGGGAACAGC
GTCGTCATGCCGTTCTGGGTGTTAGTCCGGGTAATGGCTATTTTAACGTTGCAC
TGCTGACCGAACTGCTGGGTTGGGCATGTGGTGAATTTGCACGTGTTGATGTT
GTTGTTCCGGATAGCGCACTGGAACACACCTATCTGGCACTGGGTTATGATCTG
CGTCGTGCAGCAAAAAAAGCACGTGGTGAAACCAATGTTCTGCGTAATCGTGT
TGTTCGTGCATGGGAAGCCGGTGGTGGTCCGCGTGCAAGTGATGGTCTGCAT
CGTATGAGCGAACTGGCAAGCAATGCAGCATATCGTGCAGGTCTGGCAGAATG
TGAACGTGCACTGGGTGAAGATGATCTGCTGTGGGAAACCTGTGCAGAAATGA
GCCGTGATGTTCTGGCAGCCCGTGGTCATGATGGTCCGCTGACCACCGAACG
TGTTGAACGTGCCATGCGTTATCTGACCGCAGAACTGCCGTTTTTTCTGGCAA
GCGCAGATATTTTTGGTGTTCCGAGCAGCCTGAACTTTTATCATCGTCGTCTGC
CGCTGGCAGAAGTTGTTTTTGCAGGTAAAAGCGTTCTGCAGGCACCGCCTGCA
CAGGGTTATGCAACCATTCGTCCGGCAGGTCGTGATCCTGATCGTGCAAAGCT
TGGTACCTGGAGCACAAGACTGGCCTCATGGGCCTTCCGCTCAC
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Appendix C.  List of primer sequences used in this study.  Regions in bold are FLP 
recognition targets. 
 
 
 
 
 
 
 
Primer Sequence (5' --> 3')
1NozA_SDM_F TGATGCAGCAGCACAGTGTGGTGCAG
2NozA_N114A_R CGAATACGCGCACGCAGAACGCTGGT
2NozA_N114R_R CGAATACGACGACGCAGAACGCTGGT
2NozA_V111RN114A_R CGAATACGCGCACGCAGACGGCTGGT
NozA_L131R_F GGCATATCGTAGCGTTCGTAGCGAA 
NozA_L131R_R GGATCATCCATAAAATCGCTCAGAC 
NozA_S36A_F CACTGCTGGGTGTTGCCCATGGTAA 
NozA_S36A_R CATGACCACCGGCTTTCATCAGATC 
NozA_S198L_F GTTGAAAGCACCGTTCTGTGTTATCAC 
NozA_S198L_R ACGCAGAATACGCGGTGCATCATGAA 
NozA::scarKO_F
GCCCCTCGACGCCGATGATGGGAAGGACAGCCCGTGGTGAT 
TCCGGGGATCCGTCGACC
NozA::scarKO_R
GGGTGCCGGCCCGCAGGCGGGCCGGCGGCCCCTGGATCAT 
GTAGGCTGGAGCTGCTTC
NozD::scarKO_F
GGCCGAAACGCCACGGCCCCCACCGGAGGTTCCCGTTTGAT 
TCCGGGGATCCGTCGACC
NozD::scarKO_R
TGCCGGGCCTCGCTCGGGTCCGGGCGCGGCGGCGGGTCAT 
GTAGGCTGGAGCTGCTTC
NozE::scarKO_F
CCCCGGCGCACAGAGCCGATCCCGACGGGAGACCCCTTGAT 
TCCGGGGATCCGTCGACC
NozE::scarKO_R
TGGGCGCGGGGATCGGGGACCGCCGGGCGCCGGGGTCAT 
GTAGGCTGGAGCTGCTTC
SuperpSET_F1 CATGATCGTGCTCCTGTCGT
SuperpSET_R1 CTACGGAAGGAGCTGTGGAC
SuperpSET_F2 TAAATAGCTGCGCCGATGGT
SuperpSET_R2 GTATCCTGCGTGATGAGCCA
NozACnt557_F ACTGCCGTGACCTCATGAAG
NozACnt557_R TCTCCTACCTCCAAGCCGAA
NozA_KOCon_F GCCGTTAACACCAGCTTCAC
NozA_KOCon_R GGACCTCTTCCGCCACTATG
NozD_KOCon_F ACCAGCCCGAATTCCGAAAT
NozD_KOCon_R GTGGCTGATCACCTCCCAC
NozE_KOCon_F GGTTCCCCACGATGTACCTG
NozE_KOCon_R TGCTGAAGAACCACCTCGTC
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Appendix D.  Origin and accession number (NCBI) of biochemically characterized 
CDPSs including NozA and NcdA from Nocardiopsis and characterized in this thesis.  
 
 
 
 
 
 
CDPS Origin
NCBI accession 
number
Preferential 
products
Amir_4627 Actinosynnema mirum ACU38460 c(WW)
YvmC_lic Bacillus licheniformis AAU25020 c(LL)
YvmC_sub Bacillus subtilis CAB15512 c(LL)
YvmC_thu Bacillus thuringiensis EAO57133 c(LL)
Jk0923 Corynebacterium jeikeium CAI37087 c(LL)
Rv2275 Mycobacterium tuberculosis P9WPF9 c(YY)
Nvec_CDPS2 Nematostella vectensis EDO44063 c(WX)
Ndas_1148 Nocardiopsis dassonvillei ADH66589 c(FY)
NcdA Nocardiopsis sp. CMB-M0232 KT184401 c(WW)
NozA Nocardiopsis sp. CMB-M0232 KT184400 c(WW)
Plu0297 Photorhabdus luminescens laumondii CAE12592 c(LL)
pSHaeC06 Staphylococcus haemolyticus BAE05998 c(LL)
AlbC Streptomyces noursei AAN07909 c(LF)
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Appendix E.  1H NMR (500 MHz, CDCl3) spectra confirming the chemical structure and 
purity of nocardioazine A.  
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Appendix F. 1H NMR (500 MHz, CDCl3) spectra confirming the chemical structure and 
purity of nocardioazine B.  
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